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INTRODUCTION AND STATEMENT OF RESEARCH QUESTION 
 
The behavioral states of sleep and anesthesia are defined by specific traits.  Sleep 
and anesthesia are also regulated by multiple neuromodulators in many brain regions.  
The two types of sleep, non-rapid eye movement (NREM) sleep and rapid eye movement 
(REM) sleep, are identified by analyzing specific properties of the electroencephalogram 
(EEG) and electromyogram (EMG).  The state of general anesthesia is defined by the five 
characteristic traits of unconsciousness, amnesia, analgesia, immobility, and blunted 
autonomic responses.  Although sleep and anesthesia are not the same state, anesthetics 
work at similar neural circuits that evolved to generate sleep (Franks, 2008, Kelz et al., 
2008, Lydic and Biebuyck, 1994, Lydic, 1996, Tung et al., 2005) and this point is 
discussed in more detail in the Appendix.  In order to further the mechanistic 
understanding of sleep and anesthesia (Lydic and Biebuyck, 1994), studies must 
characterize specific neuromodulators and brain regions.  Therefore, this thesis work 
focused on two neuromodulators, acetylcholine (ACh) and adenosine, and two brain 
regions, the prefrontal cortex and the pontine reticular formation.  The following 
introduction discusses the role of these neurotransmitters and brain regions in the context 
of sleep and anesthesia.  First, is a discussion of the neurochemical regulation of sleep 
and anesthesia with focus on ACh and adenosine.  The second section discusses the role 
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of the prefrontal cortex and pontine reticular formation in sleep and anesthesia.  Third, is 
a discussion of the benefits and limitations of the techniques used to obtain the thesis 
findings.  The Chapter concludes with an overview of the thesis research Aims and 
results. 
 
NEUROCHEMICAL REGULATION OF SLEEP AND ANESTHESIA 
 
Acetylcholine modulates states of sleep and wakefulness 
ACh signaling is an important component of the sleep/wake regulatory system 
(Lydic and Baghdoyan, 2005, Semba, 1999) and ACh levels vary as a function of arousal 
state.  For example, in the basal forebrain ACh release is highest during REM sleep 
compared to waking and lowest during NREM sleep (Vazquez and Baghdoyan, 2001).  
Similarly, frontal cortex (Marrosu et al., 1995), postcruciate cortex (Celesia and Jasper, 
1966), and anterior suprasylvian and postcruciate cortex (Jasper and Tessier, 1971) ACh 
levels coming from cholinergic basal forebrain neurons are highest during wakefulness 
and REM sleep compared to NREM sleep.  In the brainstem pontine reticular formation 
ACh release is highest during REM sleep compared to waking or NREM sleep (Kodama 
et al., 1990, Leonard and Lydic, 1995, Leonard and Lydic, 1997).  In humans, systemic 
administration of the acetylcholinesterase inhibitor physostigmine during REM sleep 
caused the subjects to wake-up whereas systemic administration of physostigmine during 
NREM sleep induced REM sleep (Sitaram et al., 1976).  These data are consistent with 
the interpretation that enhanced cholinergic neurotransmission increases cortically 
activated states of arousal. 
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Isoflurane anesthesia alters cholinergic neurotransmission 
Isoflurane modulates nicotinic (Flood et al., 1997, Flood and Coates, 2002, 
Matsuura et al., 2002, Violet et al., 1997, Yamashita et al., 2005) and muscarinic (Do et 
al., 2001, Hudetz et al., 2003, Nietgen et al., 1998) cholinergic receptors and the release 
of ACh.  Nicotinic receptors are comprised of five subunits and several studies have 
investigated the role of various nicotinic ACh receptor subunits in the mechanism of 
action of volatile anesthetics (Violet et al., 1997).  Isoflurane at clinically relevant 
concentrations inhibits neuronal nicotinic ACh receptor currents expressed in vitro when 
the receptors contain the α4-β2 subunit combination (Yamashita et al., 2005).  Isoflurane 
does not block the response of homomeric α7 nicotinic receptors to ACh when the 
anesthetic and the agonist are coadministered (Flood et al., 1997).  However, clinically 
relevant concentrations of isoflurane do inhibit homomeric α7 nicotinic receptors when 
the anesthetic is applied prior to ACh, or when ACh is applied in high concentrations 
(Flood and Coates, 2002).  These findings may be relevant in vivo, because α7 nicotinic 
receptors are present in the brain (Flood and Coates, 2002), and synaptic levels of ACh 
has been estimated to reach concentrations in the micromolar to millimolar range (Phillis, 
2005).  The effects of isoflurane on native (i.e., non-recombinant) nicotinic receptors also 
have been investigated (Matsuura et al., 2002).  Interestingly, both isoflurane and a 
structurally similar halogenated molecule, 1,2-dichlorohexafluorocyclobutane, that does 
not cause immobility but does have amnestic properties inhibit native neuronal nicotinic 
ACh receptors in rat medial habenula neurons (Matsuura et al., 2002).  Another 
structurally similar agent, 2,3-dichlorooctafluorobutane, with neither immobilizing or 
amnestic properties does not block nicotinic receptor-mediated currents (Matsuura et al., 
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2002).  These data suggest that the amnestic effects of isoflurane may be mediated, in 
part, by nicotinic receptors in the medial habenula.  More in vivo studies are needed to 
determine if nicotinic ACh receptors are relevant for the production of anesthesia by 
isoflurane.  
There are five muscarinic cholinergic receptor subtypes, and isoflurane has been 
shown to inhibit M3 but not M1 muscarinic receptors (Nietgen et al., 1998).  M1 and M3 
receptors are structurally quite similar, thus different effects of the same anesthetic on 
these two subtypes implies that the binding site of action is quite specific.  More recently, 
the same investigators showed that isoflurane-induced inhibition of M3 receptor signaling 
is mediated by an increase in protein kinase C activity, but the site of action on the M3 
receptor has not yet been localized (Do et al., 2001).  Another study found that 
intracerebroventricular administration of the acetylcholinesterase inhibitor neostigmine or 
the muscarinic agonist oxotremorine to isoflurane anesthetized rats increases spontaneous 
limb and orofacial exploratory movements, indicating increased arousal (Hudetz et al., 
2003).  These data are consistent with the interpretation that activation of central 
cholinergic neurotransmission can reverse some aspects of isoflurane anesthesia. 
Studies of intact brain using in vivo microdialysis report that isoflurane causes a 
dose dependent decrease in ACh release in rat cerebral cortex (Dong et al., 2006, 
Shichino et al., 1997), rat striatum (Shichino et al., 1997), and cat pontine reticular 
formation (Keifer et al., 1996).   The effect of isoflurane on ACh release varies with age.  
Isoflurane causes a significantly larger decrease in prefrontal cortex ACh release in old 
versus young rats (Jansson et al., 2004).  Future studies are needed to determine whether 
aged rats show performance or memory deficits following isoflurane anesthesia.  Such a 
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finding would support the interpretation that isoflurane-induced decreases in prefrontal 
cortex ACh release may contribute to increased post-operative delirium in the elderly.  A 
discussion of the role of cholinergic neurotransmission on other anesthetics (pg 99-101, 
106-108, 117-118, and 121-122) and of isoflurane on other neurotransmitters (pg 110-
119) can be found in the Appendix. 
 
Adenosinergic modulation of sleep and wakefulness 
Adenosine is a sleep promoting neuromodulator that increases in the basal 
forebrain and cortex during prolonged wakefulness (Porkka-Heiskanen et al., 2000).  The 
breakdown product of adenosine triphosphate, adenosine is ubiquitously distributed 
throughout the brain (Dunwiddie and Masino, 2001).  Extracellular adenosine levels are 
regulated by a bidirectional nucleoside transporter (Latini and Pedata, 2001).  There are 
four G-protein coupled receptor subtypes A1, A2A, A2B, and A3 of adenosine receptors 
(Ribeiro et al., 2002).  Caffeine, the most commonly used psychoactive stimulant, 
promotes wakefulness by antagonizing adenosine A1 and A2A receptors (Fredholm et al., 
1999).   
 
Adenosine decreases isoflurane anesthesia requirements 
Peroperative adenosine infusion in humans undergoing breast surgery decreases 
isoflurane requirement and decreases postoperative analgesic requirement (Segerdahl et 
al., 1995).  A similar study of patients undergoing shoulder surgery showed that 
adenosine reduces the requirement for isoflurane but has no effect on postoperative 
analgesic requirement (Segerdahl et al., 1996).  Although adenosine is well recognized to 
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have antinociceptive effects (Boison, 2008), few studies have examined the possible role 
of adenosine contributing to the anesthetic effects of isoflurane.  In rat, isoflurane-
induced reductions in focal cerebral ischemia are blocked by an adenosine A1 receptor 
antagonist, indicating that this neuroprotective effect of isoflurane may be mediated by 
adenosine A1 receptors (Liu et al., 2006).  Isoflurane-induced activation of adenosine A1 
receptors in primary cultures of rat hippocampal neurons also suppresses spontaneous 
calcium oscillations (Tas et al., 2003).  This study suggests that another mechanism by 
which isoflurane may be neuroprotective is by increasing adenosine levels (Tas et al., 
2003).  A discussion of the role of adenosinergic neurotransmission on other anesthetics 
can be found in the Appendix (pg 101-102, 108, 119, and 122). 
 
BEHAVIORAL STATE MODULATION BY THE PREFRONTAL CORTEX AND 
THE PONTINE RETICULAR FORMATION 
 
The prefrontal cortex is deactivated during sleep and anesthesia 
The prefrontal cortex regulates executive functions such as working memory, a 
sense of time, controlling inhibition (Fuster, 2001), and attention (Sarter et al., 2006).  
Sleep deprivation strongly impairs prefrontal cortex functions such as psychomotor 
vigilance (Muzur et al., 2002). In the elderly, prefrontal cortex slow wave activity during 
NREM sleep is correlated with better performance (Anderson and Horne, 2003).  During 
the unconsciousness states of sleep (Stickgold et al., 2001) and anesthesia (Andrade, 
1996) the prefrontal cortex is deactivated.  However, during REM sleep where much of 
the cortex is reactivated, the dorsolateral prefrontal cortex remains deactivated, and this 
deactivation likely accounts for the different sense of self awareness and time that occurs 
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in dreams (Muzur et al., 2002).   
Further support that the prefrontal cortex contributes to arousal state control 
comes from studies demonstrating changes in prefrontal cortex neurotransmitters across 
the sleep wake cycle.  For example, extracellular levels of serotonin in the prefrontal 
cortex are higher during wakefulness compared to NREM sleep (de Saint Hilaire et al., 
2000) whereas prefrontal cortex dopamine levels are highest during wakefulness and 
REM sleep compared to NREM sleep in rat (Lena et al., 2005).  Cortical ACh levels also 
varies across the sleep wake cycle being highest during the activated states of 
wakefulness and REM sleep (Marrosu et al., 1995), (Celesia and Jasper, 1966), (Jasper 
and Tessier, 1971). 
 
The pontine reticular formation contributes to the regulation of sleep and anesthesia 
 Early brain transection studies by Jouvet (Jouvet, 1962) demonstrated that the 
pontine reticular formation was necessary for the generation of NREM and REM sleep.  
Both lesions of the pontine reticular formation in humans (Autret et al., 1988, Gironell et 
al., 1995, Kimura et al., 2000, Kushida et al., 1991, Lavie et al., 1984) and lesions of the 
cholinergic dorsolateral pontomesencephalic tegmentum in non-human animals (Webster 
and Jones, 1988) cause disruption of REM sleep.  In the pontine reticular formation, ACh 
release is highest during REM sleep compared to wakefulness and NREM sleep (Kodama 
et al., 1990, Leonard and Lydic, 1995, Leonard and Lydic, 1997).  Cholinomimetics 
delivered to the pontine reticular formation induce a REM sleep-like state in cat 
(Baghdoyan et al., 1984), rat (Bourgin et al., 1995), and mouse (Lydic et al., 2002).  The 
pontine reticular formation also contributes to regulation of attention.  When humans 
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perform attention demanding tasks, the pontine reticular formation is activated as 
measured by positron emission tomography (Kinomura et al., 1996).  Anesthetics 
modulate pontine reticular formation neurotransmission as demonstrated by a decrease in 
ACh release within the pontine reticular formation caused by halothane in cat (Keifer et 




The mouse model: a tool for studies of arousal state control  
The C57BL/6J (B6) mouse genome has been sequenced and shares 99% 
homology with the human genome (Mouse Genome Sequencing Consortium, 2002).  
This similarity with the human genome and known genomic sequence provides the 
rationale for use of mice in the current thesis studies.  This remarkable homology implies 
that studies using mice have the potential to establish links, relevant for humans, between 
physiological and behavioral phenotypes and their underlying causal genotype.  
Considerable evidence supports the view that understanding genetic modulation of 
normal phenotypes will ultimately make it possible to develop molecular therapy targeted 
at specific human diseases (Balicki and Beutler, 2002, Green et al., 2000, Hollams et al., 
2002, Sakamoto, 2004).  Thus, these thesis studies used B6 mice to investigate the role of 
prefrontal cortex adenosine A1 and A2A receptors in arousal state control.   
Knowledge of the mouse genome has been useful for the development of 
knockout models where a specific gene can be deleted and the resulting phenotype 
analyzed.  An acknowledged limitation of knockout models is that the absence of the 
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gene during development can cause compensatory changes and lead to differences in the 
adult animal that are not due to the gene of interest (Robert, 1998).  One way to 
circumvent this problem is to use conditional knockout mice with promoters such as 
CAMKII that do not eliminate the gene until after primary development (Wang et al., 
2003).  In a study related to this thesis work, adenosine A1 or A2A receptor knockout mice 
were given caffeine and only the adenosine A2A receptor knockout mice showed no 
enhancement of wakefulness by caffeine (Huang et al., 2005).  The authors of this study 
interpreted this result to suggest that caffeine promotes wakefulness through the 
adenosine A2A receptor and not the adenosine A1 receptor.  In contrast to this finding in 
knockout mice, the results of the present thesis work using intact B6 mice revealed that 
both adenosine A1 and A2A receptors in the prefrontal cortex contribute to the regulation 
of cortical and behavioral arousal.        
 
Measures of behavioral arousal 
EEG Analysis: The behavioral arousal state of human and non-human animals 
can be determined by analyzing the EEG.  The present thesis work used fast Fourier 
transform (FFT) analysis to quantify the power at a given frequency of the EEG 
waveform (Pigeau et al., 1981).  This analysis yields a graphical representation of the 
characteristics of the EEG.  During the cortically activated states of wakefulness and 
REM sleep, many neurons fire in a fast desynchronized pattern resulting in a low 
amplitude high frequency EEG (Campbell et al., 2006, Subasi, 2005, Sussman et al., 
1979, Zhang et al., 2008).  During the cortically deactivated states of NREM sleep and 
anesthesia, neuronal firing is synchronized resulting in a large amplitude slow frequency 
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EEG (Campbell et al., 2006, Subasi, 2005, Sussman et al., 1979, Zhang et al., 2008).  The 
EEG waveform and power at a given EEG frequency provide standard tools for 
objectively classifying behavioral states as wakefulness, NREM sleep, or REM sleep.  
These EEG and FFT characteristics are homologous to those observed in the human 
EEG.  This excellent homology makes it possible for pre-clinical studies of behavioral 
state control using non-human animals to elucidate the cellular and molecular 
mechanisms regulating sleep in humans. 
Recovery of righting response: The righting response is a well established 
measure of recovery from various hypnotics ranging from anesthetics (Straw and 
Mitchell, 1967) to drugs of abuse such as ethanol (Melchior and Allen, 1993) and opioids 
(Sakai et al., 2002).  The righting response after inhaled anesthetics in mice (DeMarco et 
al., 2004) and rats (Ishizawa, 2000) has been used to further delineate the cholinergic 
mechanisms of anesthetic action.  The present thesis work used the righting response 
after isoflurane anesthesia in mouse as a measure of behavioral arousal in response to 
adenosine receptor agonists and antagonists. 
 
In vivo microdialysis 
Microdialysis has revolutionized the study of brain neurochemistry because it 
permits brain region specific measurement of neurotransmitters (Benveniste and 
Huttemeier, 1990, Jin et al., 2008, Robinson and Justice, 1991, Watson et al., 2006) as 
well as pharmacological manipulation of local environments (Hocht et al., 2007, Li et al., 
2006, Pan et al., 2007, Yu et al., 2007).  Microdialysis probes consist of a semipermeable 
membrane where molecules, such as neurotransmitters or drugs, diffuse across their 
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concentration gradient both in and out of the probe.  CMA/7 dialysis probes used in the 
present thesis research are estimated to deliver about 5% of the dialysate drug 
concentration.  This estimate comes from in vitro analysis of the probes ability to 
recovery a known concentration of acetylcholine.  Many factors affect diffusion across 
the dialysis probe membrane including dialysate composition, dialysate flow rate, the 
molecular weight cut off of the membrane, temperature, and the environment surrounding 
the probe membrane (Watson et al., 2006).  The following discusses these factors in 
relation to differences between in vitro and in vivo studies.  The dialysate (Ringer’s) is 
isotonic with cerebral spinal fluid to minimize ion and fluid diffusion across the 
membrane.  The dialysate flow rate was held constant at 2 µl/min, a commonly used flow 
rate for in vivo microdialysis studies (Coleman et al., 2006).  The molecular weight cut 
off of the membrane (6 kD) is factory determined and stays constant across all 
experiments.  The dialysate composition, flow rate, and membrane cut off are the same 
for both in vitro and in vivo studies.  One difference between in vitro and in vivo studies 
is the temperature.  In vitro probe recoveries are collected at room temperature (~21 
degrees C) whereas the in vivo samples are collected at (~37 degrees C).  This increase in 
temperature will slightly increase diffusion across the probe membrane compared to our 
in vitro probe recovery conditions.  However, as discussed below, this slight increase in 
diffusion does not increase diffusion greater than the inhibitory factors present by placing 
the probe in brain tissue.  For example, the environment surrounding the probe affects 
diffusion and also differs between in vitro and in vivo studies.  In vivo, there are neurons 
and glial cells surrounding the probe that impede direct diffusion (tortuosity) to the 
dialysis membrane (Benveniste and Huttemeier, 1990, Watson et al., 2006), whereas, in 
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vitro, the probe is surrounded by a homogenous solution.  The homogenous solution 
gives the best case diffusion scenario across the probe membrane.  While in vitro 
recovery of acetylcholine measures the ability of a molecule outside the probe to get into 
the probe, and in vivo drug delivery is the ability of a drug inside the probe to get out of 
the probe, the same membrane properties determine the outcome of diffusion in or out of 
the probe.  Despite the many variables that affect microdialysis, the drugs tested in the 
present thesis studies caused significant changes in cortical and pontine reticular 
formation ACh release, anesthesia recovery time, and EEG delta power, demonstrating 
the robust nature of the results.    
 
OVERVIEW OF RESEARCH GOALS AND FINDINGS 
 
The unifying goal for this thesis research was to characterize cholinergic and 
adenosinergic mechanisms in the prefrontal cortex of B6 mouse that contribute to arousal 
state control.  The prefrontal cortex has multiple regulatory roles including the temporal 
organization of behavior (Fuster, 2001), working memory (Gabrieli et al., 1998, 
Goldman-Rakic, 1996), regulation of behavioral arousal (Horne, 1993, Muzur et al., 
2002), controlling inhibition (Fuster, 2001) and autonomic regulation (Groenewegen and 
Uylings, 2000).  The rationale for focusing on the prefrontal cortex as an important 
region for arousal state control is provided by evidence that sleep deprivation impairs 
many functions subserved by the prefrontal cortex, and the prefrontal cortex is 
deactivated during sleep (Stickgold et al., 2001) and anesthesia (Andrade, 1996).  
Prefrontal cortex ACh is essential for normal cognitive function (Sarter and Bruno, 1997, 
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Yu and Dayan, 2002) and prefrontal cortex ACh levels increase during tasks that require 
attention (Kozak et al., 2006, Passetti et al., 2000).  Cognitive performance decreases 
with prolonged wakefulness (Thomas et al., 2000) and during prolonged wakefulness, 
adenosine levels rise within the basal forebrain and cortex to promote sleep (Porkka-
Heiskanen et al., 2000).  Further evidence that adenosine promotes sleep is supported by 
the fact that the most commonly used psychoactive stimulant caffeine, is an adenosine A1 
and A2A receptor antagonist (Fredholm et al., 1999).  There is debate in the field as to 
which adenosine receptor subtype is more important for the role of adenosine in arousal 
state control.  Available evidence supports both adenosine A1 (Basheer et al., 2001, 
Benington et al., 1995, Yanik and Radulovacki, 1987) and A2A (Huang et al., 2005, 
Stenberg et al., 2003, Urade et al., 2003) receptors in the regulation of behavioral arousal 
by adenosine.  The exact role of specific receptor subtypes vary as a function of brain 
region (Fredholm et al., 2005, Ribeiro et al., 2002).  Although data make clear that 
adenosine promotes sleep and ACh promotes arousal, the interaction between these two 
neurotransmitter systems in the prefrontal cortex remain incompletely understood.  The 
following aims of this thesis research were designed to provide insight into the 
mechanisms through which adenosinergic and cholinergic neurotransmission in the 
prefrontal cortex modulate behavioral arousal.  
 




Specific Aim 1 tested the hypothesis that adenosine A1 and A2A receptors in 
the prefrontal cortex of B6 mouse modulate cortical ACh release, behavioral 
arousal, and EEG delta power.  Aim 1 results are reported in Chapter 2.  Aim 1 used in 
vivo microdialysis to deliver adenosine A1 and A2A receptor agonists and antagonists to 
the prefrontal cortex of isoflurane anesthetized B6 mice.  Prefrontal cortex ACh release, 
anesthesia recovery time, and EEG delta power were quantified.  The adenosine A2A 
receptor agonist CGS was delivered to the prefrontal cortex by microdialysis.  These 
studies made it possible to evaluate the extent to which prefrontal cortex ACh release was 
modulated by adenosine A2A receptors.  CGS caused a concentration dependent increase 
in prefrontal cortex ACh release and decrease in anesthesia recovery time.  These CGS-
induced alterations in ACh release and anesthesia recovery time were blocked by 
coadministration of the adenosine A2A receptor antagonist ZM.  CGS also decreased 
cortical EEG delta power.  The results showed for the first time that activation of 
adenosine A2A receptors in the prefrontal cortex promotes waking phenotypes (Van Dort 
CJ et al., 2007a).  In contrast, microdialysis delivery of the adenosine A1 receptor agonist 
SPA to the prefrontal cortex caused a concentration dependent decrease in prefrontal 
cortex ACh release and delayed anesthesia recovery time.  Coadministration of SPA with 
the adenosine A1 receptor antagonist DPCPX blocked the SPA-induced decrease in ACh 
release and increase in anesthesia recovery time (Van Dort CJ et al., 2006a).  Consistent 
with the interpretation that activation of adenosine A1 receptors in the prefrontal cortex 
decreases waking phenotypes, SPA also increased cortical EEG delta power.  Having 
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demonstrated that activation of prefrontal cortex adenosine A1 and A2A receptors by the 
exogenous agonists altered ACh release, anesthesia recovery time, and EEG delta power, 
the next set of experiments was designed to determine if the endogenous molecule, 
adenosine, also modulates these waking phenotypes.  Dialysis delivery of the adenosine 
A1 and A2A receptor antagonist caffeine or the adenosine A1 receptor antagonist DPCPX 
caused a concentration dependent increase in ACh release and decrease in anesthesia 
recovery time (Van Dort CJ et al., 2006b).  EEG delta power was decreased by both 
caffeine and DPCPX, whereas the adenosine A2A receptor antagonist ZM did not alter 
ACh release, anesthesia recovery time, or EEG delta power.  The results are consistent 
with the interpretation that endogenous adenosine in the prefrontal cortex inhibits waking 
phenotypes through adenosine A1 receptors.  Taken together, these data from Aim 1 
support the conclusion that adenosine A1 receptors in the prefrontal cortex of B6 mouse 
modulate arousal and suggest that caffeine promotes arousal, in part, through prefrontal 
cortex adenosine A1 receptor blockade. 
 
Specific Aim 2 tested the hypothesis that blockade of adenosine A1 receptors 
in the prefrontal cortex increases wakefulness and decreases sleep.  The results of 
Aim 2 are shown in Chapter 2.  Acetylcholine and adenosine levels vary with arousal 
state of the animal, therefore the Aim 1 studies described above used isoflurane 
anesthesia to hold arousal state constant.  In order to determine if prefrontal cortex 
adenosine A1 receptors also modulate the naturally occurring states of sleep and 
wakefulness, Aim 2 used unanesthetized intact behaving mice implanted with EEG and 
EMG electrodes and a guide tube aimed for the prefrontal cortex.  The states of sleep and 
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wakefulness were quantified for 2 h following microinjection of DPCPX or saline 
(vehicle control).  DPCPX caused a significant increase in wakefulness and decrease in 
NREM sleep but did not change REM sleep (Van Dort CJ et al., 2007b).  These data 
from intact freely behaving mice further support the Aim 1 conclusion that activation of 
prefrontal cortex adenosine A1 receptors by endogenous adenosine not only modulates 
the waking phenotypes of increased ACh release, decreased anesthesia recovery time, 
and decreased EEG delta power but also inhibits wakefulness. 
 
Specific Aim 3 tested the hypothesis that adenosine A1 and A2A receptors in 
the prefrontal cortex modulate ACh release in the pontine reticular formation.  Aim 
3 findings are reported in Chapter 3.  Early brain transection studies (Jouvet, 1962) 
revealed that rhythmic oscillations between the physiological signs of NREM sleep and 
REM sleep persist after the forebrain is removed.  These studies helped localize the 
central pattern generator for REM and NREM sleep to the pontine brainstem.  Aim 1 and 
2 results showed that adenosine receptors in the prefrontal cortex modulate EEG, 
behavioral arousal, and sleep.  In view of early studies showing that rostral brain regions 
are not necessary for generating the ultradian rhythm of REM and NREM sleep, the Aim 
1 and 2 results imply that the prefrontal cortex modulates states of sleep and wakefulness 
by way of descending input to caudal arousal control centers.  Therefore, Aim 3 was 
designed to determine if prefrontal cortex adenosine receptors modulate pontine reticular 
formation ACh release.  The Aim 3 results indicate that microdialysis delivery of the 
adenosine A2A receptor agonist CGS to the prefrontal cortex increased pontine reticular 
formation ACh release whereas microdialysis delivery of the adenosine A1 receptor 
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agonist SPA to the prefrontal cortex decreased pontine reticular formation ACh release.  
These findings are the first to demonstrate that pharmacological manipulation of the 
prefrontal cortex can alter neurotransmitter release in the pontine reticular formation.  
This finding also suggests that one mechanism by which prefrontal cortex adenosine A1 
and A2A receptors modulate behavioral arousal is by altering pontine reticular formation 
ACh release.  The next set of studies was designed to determine if endogenous adenosine 
also modulates behavioral arousal through pontine reticular formation ACh release.  
Blocking a receptor with an antagonist permits the inference that the endogenous 
neurotransmitter for that receptor modulates the dependent measure being quantified.  
Therefore, the adenosine A1 and A2A receptor antagonist caffeine or the adenosine A1 
receptor antagonist DPCPX were delivered by microdialysis to the prefrontal cortex.  
Both drugs caused a significant increase in pontine reticular formation ACh release.  
Taken together, these data are consistent with the interpretation that endogenous 
adenosine in the prefrontal cortex modulates arousal, in part, by altering pontine reticular 
formation ACh release.   
 




Anderson C, Horne JA. Prefrontal cortex: links between low frequency delta EEG in 
sleep and neuropsychological performance in healthy, older people. 
Psychophysiology 40: 349-357, 2003. 
 
Andrade J. Investigations of hypesthesia: using anesthetics to explore relationships 
between consciousness, learning, and memory. Conscious Cogn 5: 562-580, 1996. 
 
Autret A, Laffont F, de Toffol B, Cathala HP. A syndrome of REM and non-REM sleep 
reduction and lateral gaze paresis after medial tegmental pontine stroke. 
Computed tomographic scans and anatomical correlations in four patients. Arch 
Neurol 45: 1236-1242, 1988. 
 
Baghdoyan HA, Monaco AP, Rodrigo-Angulo ML, Assens F, McCarley RW, Hobson 
JA. Microinjection of neostigmine into the pontine reticular formation of cats 
enhances desynchronized sleep signs. J Pharmacol Exp Ther 231: 173-180, 1984. 
 
Balicki D, Beutler E. Gene therapy of human disease. Medicine (Baltimore) 81: 69-86, 
2002. 
 
Basheer R, Halldner L, Alanko L, McCarley RW, Fredholm BB, Porkka-Heiskanen T. 
Opposite changes in adenosine A1 and A2A receptor mRNA in the rat following 
sleep deprivation. Neuroreport 12: 1577-1580, 2001. 
 
Benington JH, Kodali SK, Heller HC. Stimulation of A1 adenosine receptors mimics the 
electroencephalographic effects of sleep deprivation. Brain Res 692: 79-85, 1995. 
 
Benveniste H, Huttemeier PC. Microdialysis--theory and application. Prog Neurobiol 35: 
195-215, 1990. 
 
Boison D. Adenosine as a neuromodulator in neurological diseases. Curr Opin 
Pharmacol 8: 2-7, 2008. 
 
Bourgin P, Escourrou P, Gaultier C, Adrien J. Induction of rapid eye movement sleep by 
carbachol infusion into the pontine reticular formation in the rat. Neuroreport 6: 
532-536, 1995. 
 
Campbell IG, Higgins LM, Darchia N, Feinberg I. Homeostatic behavior of fast Fourier 
transform power in very low frequency non-rapid eye movement human 
electroencephalogram. Neuroscience 140: 1395-1399, 2006. 
 
Celesia GG, Jasper HH. Acetylcholine released from cerebral cortex in relation to state of 
activation. Neurology 16: 1053-1063, 1966. 
 
   
 19 
Coleman CG, Baghdoyan HA, Lydic R. Dialysis delivery of an adenosine A2A agonist 
into the pontine reticular formation of C57BL/6J mouse increases pontine 
acetylcholine release and sleep. J Neurochem 96: 1750-1759, 2006. 
 
de Saint Hilaire Z, Orosco M, Rouch C, Python A, Nicolaidis S. Neuromodulation of the 
prefrontal cortex during sleep: a microdialysis study in rats. Neuroreport 11: 
1619-1624, 2000. 
 
DeMarco GJ, Baghdoyan HA, Lydic R. Carbachol in the pontine reticular formation of 
C57BL/6J mouse decreases acetylcholine release in prefrontal cortex. 
Neuroscience 123: 17-29, 2004. 
 
Do SH, Kamatchi GL, Durieux ME. The effects of isoflurane on native and chimeric 
muscarinic acetylcholine receptors: the role of protein kinase C. Anesth Analg 93: 
375-381, 2001. 
 
Dong HL, Fukuda S, Murata E, Higuchi T. Excitatory and inhibitory actions of isoflurane 
on the cholinergic ascending arousal system of the rat. Anesthesiology 104: 122-
133, 2006. 
 
Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous 
system. Annu Rev Neurosci 24: 31-55, 2001. 
 
Flood P, Ramirez-Latorre J, Role L. Alpha4 β2 neuronal nicotinic acetylcholine receptors 
in the central nervous system are inhibited by isoflurane and propofol, but α7-
type nicotinic acetylcholine receptors are unaffected. Anesthesiology 86: 859-865, 
1997. 
 
Flood P, Coates KM. Sensitivity of the α7 nicotinic acetylcholine receptor to isoflurane 
may depend on receptor inactivation. Anesth Analg 95: 83-87, 2002. 
 
Franks NP. General anaesthesia: from molecular targets to neuronal pathways of sleep 
and arousal. Nat Rev Neurosci 9: 370-386, 2008. 
 
Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain 
with special reference to factors that contribute to its widespread use. Pharmacol 
Rev 51: 83-133, 1999. 
 
Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM. Adenosine and brain 
function. Int Rev Neurobiol 63: 191-270, 2005. 
 
Fuster JM. The prefrontal cortex--an update: time is of the essence. Neuron 30: 319-333, 
2001. 
 
Gabrieli JD, Poldrack RA, Desmond JE. The role of left prefrontal cortex in language and 
memory. Proc Natl Acad Sci USA 95: 906-913, 1998. 
   
 20 
 
Gironell A, de la Calzada MD, Sagales T, Barraquer-Bordas L. Absence of REM sleep 
and altered non-REM sleep caused by a haematoma in the pontine tegmentum. J 
Neurol Neurosurg Psychiatry 59: 195-196, 1995. 
 
Goldman-Rakic PS. The prefrontal landscape: implications of functional architecture for 
understanding human mentation and the central executive. Philos Trans R Soc 
Lond B Biol Sci 351: 1445-1453, 1996. 
 
Green DW, Roh H, Pippin J, Drebin JA. Antisense oligonucleotides: an evolving 
technology for the modulation of gene expression in human disease. J Am Coll 
Surg 191: 93-105, 2000. 
 
Groenewegen HJ, Uylings HB. The prefrontal cortex and the integration of sensory, 
limbic and autonomic information. Prog Brain Res 126: 3-28, 2000. 
 
Hocht C, Opezzo JA, Taira CA. Applicability of reverse microdialysis in 
pharmacological and toxicological studies. J Pharmacol Toxicol Methods 55: 3-
15, 2007. 
 
Hollams EM, Giles KM, Thomson AM, Leedman PJ. MRNA stability and the control of 
gene expression: implications for human disease. Neurochem Res 27: 957-980, 
2002. 
 
Horne JA. Human sleep, sleep loss and behaviour. Implications for the prefrontal cortex 
and psychiatric disorder. Br J Psychiatry 162: 413-419, 1993. 
 
Huang ZL, Qu WM, Eguchi N, Chen JF, Schwarzschild MA, Fredholm BB, Urade Y, 
Hayaishi O. Adenosine A2A, but not A1, receptors mediate the arousal effect of 
caffeine. Nat Neurosci 8: 858-859, 2005. 
 
Hudetz AG, Wood JD, Kampine JP. Cholinergic reversal of isoflurane anesthesia in rats 
as measured by cross-approximate entropy of the electroencephalogram. 
Anesthesiology 99: 1125-1131, 2003. 
 
Ishizawa Y. Selective blockade of muscarinic receptor subtypes in the brain stem 
reticular formation in rats: effects on anesthetic requirements. Brain Res 873: 124-
126, 2000. 
 
Jansson A, Olin K, Yoshitake T, Hagman B, Herrington MK, Kehr J, Permert J. Effects 
of isoflurane on prefrontal acetylcholine release and hypothalamic Fos response in 
young adult and aged rats. Exp Neurol 190: 535-543, 2004. 
 
Jasper HH, Tessier J. Acetylcholine liberation from cerebral cortex during paradoxical 
(REM) sleep. Science 172: 601-602, 1971. 
 
   
 21 
Jin G, Cheng Q, Feng J, Li F. On-line microdialysis coupled to analytical systems. J 
Chromatogr Sci 46: 276-287, 2008. 
 
Jouvet M. Research on the neural structures and responsible mechanisms in different 
phases of physiological sleep. Arch Ital Biol 100: 125-206, 1962. 
 
Keifer JC, Baghdoyan HA, Lydic R. Pontine cholinergic mechanisms modulate the 
cortical electroencephalographic spindles of halothane anesthesia. Anesthesiology 
84: 945-954, 1996. 
 
Kelz MB, Sun Y, Chen J, Cheng Meng Q, Moore JT, Veasey SC, Dixon S, Thornton M, 
Funato H, Yanagisawa M. An essential role for orexins in emergence from 
general anesthesia. Proc Natl Acad Sci USA 105: 1309-1314, 2008. 
 
Kimura K, Tachibana N, Kohyama J, Otsuka Y, Fukazawa S, Waki R. A discrete pontine 
ischemic lesion could cause REM sleep behavior disorder. Neurology 55: 894-
895, 2000. 
 
Kinomura S, Larsson J, Gulyas B, Roland PE. Activation by attention of the human 
reticular formation and thalamic intralaminar nuclei. Science 271: 512-515, 1996. 
 
Kodama T, Takahashi Y, Honda Y. Enhancement of acetylcholine release during 
paradoxical sleep in the dorsal tegmental field of the cat brain stem. Neurosci Lett 
114: 277-282, 1990. 
 
Kozak R, Bruno JP, Sarter M. Augmented prefrontal acetylcholine release during 
challenged attentional performance. Cereb Cortex 16: 9-17, 2006. 
 
Kushida CA, Rye DB, Nummy D, Milton JG, Spire JP, Rechtschaffen A. Cortical 
asymmetry of REM sleep EEG following unilateral pontine hemorrhage. 
Neurology 41: 598-601, 1991. 
 
Latini S, Pedata F. Adenosine in the central nervous system: release mechanisms and 
extracellular concentrations. J Neurochem 79: 463-484, 2001. 
 
Lavie P, Pratt H, Scharf B, Peled R, Brown J. Localized pontine lesion: nearly total 
absence of REM sleep. Neurology 34: 118-120, 1984. 
 
Lena I, Parrot S, Deschaux O, Muffat-Joly S, Sauvinet V, Renaud B, Suaud-Chagny MF, 
Gottesmann C. Variations in extracellular levels of dopamine, noradrenaline, 
glutamate, and aspartate across the sleep--wake cycle in the medial prefrontal 
cortex and nucleus accumbens of freely moving rats. J Neurosci Res 81: 891-899, 
2005. 
 
Leonard TO, Lydic R. Nitric oxide synthase inhibition decreases pontine acetylcholine 
release. Neuroreport 6: 1525-1529, 1995. 
   
 22 
 
Leonard TO, Lydic R. Pontine nitric oxide modulates acetylcholine release, rapid eye 
movement sleep generation, and respiratory rate. J Neurosci 17: 774-785, 1997. 
 
Li Y, Peris J, Zhong L, Derendorf H. Microdialysis as a tool in local pharmacodynamics. 
AAPS J 8: E222-E235, 2006. 
 
Liu Y, Xiong L, Chen S, Wang Q. Isoflurane tolerance against focal cerebral ischemia is 
attenuated by adenosine A1 receptor antagonists. Can J Anaesth 53: 194-201, 
2006. 
 
Lydic R, Biebuyck JF. Sleep neurobiology: relevance for mechanistic studies of 
anaesthesia. Br J Anaesth 72: 506-508, 1994. 
 
Lydic R. Reticular modulation of breathing during sleep and anesthesia. Curr Opin Pulm 
Med 2: 474-481, 1996. 
 
Lydic R, Douglas CL, Baghdoyan HA. Microinjection of neostigmine into the pontine 
reticular formation of C57BL/6J mouse enhances rapid eye movement sleep and 
depresses breathing. Sleep 25: 835-841, 2002. 
 
Lydic R, Baghdoyan HA. Sleep, anesthesiology, and the neurobiology of arousal state 
control. Anesthesiology 103: 1268-1295, 2005. 
 
Marrosu F, Portas C, Mascia MS, Casu MA, Fa M, Giagheddu M, Imperato A, Gessa 
GL. Microdialysis measurement of cortical and hippocampal acetylcholine release 
during sleep-wake cycle in freely moving cats. Brain Res 671: 329-332, 1995. 
 
Matsuura T, Kamiya Y, Itoh H, Higashi T, Yamada Y, Andoh T. Inhibitory effects of 
isoflurane and nonimmobilizing halogenated compounds on neuronal nicotinic 
acetylcholine receptors. Anesthesiology 97: 1541-1549, 2002. 
 
Melchior CL, Allen PM. Temperature in mice after ethanol: effect of probing and regain 
of righting reflex. Alcohol 10: 17-20, 1993. 
 
Mouse Genome Sequencing Consortium. Initial sequencing and comparative analysis of 
the mouse genome. Nature 420: 520-562, 2002. 
 
Muzur A, Pace-Schott EF, Hobson JA. The prefrontal cortex in sleep. Trends Cogn Sci 6: 
475-481, 2002. 
 
Nietgen GW, Honemann CW, Chan CK, Kamatchi GL, Durieux ME. Volatile 
anaesthetics have differential effects on recombinant m1 and m3 muscarinic 
acetylcholine receptor function. Br J Anaesth 81: 569-577, 1998. 
 
   
 23 
Pan YF, Feng J, Cheng QY, Li FZ. Intracerebral microdialysis technique and its 
application on brain pharmacokinetic-pharmacodynamic study. Arch Pharm Res 
30: 1635-1645, 2007. 
 
Passetti F, Dalley JW, O'Connell MT, Everitt BJ, Robbins TW. Increased acetylcholine 
release in the rat medial prefrontal cortex during performance of a visual 
attentional task. Eur J Neurosci 12: 3051-3058, 2000. 
 
Phillis JW. Acetylcholine release from the central nervous system: a 50-year 
retrospective. Crit Rev Neurobiol 17: 161-217, 2005. 
 
Pigeau RA, Hoffmann RF, Moffitt AR. A multivariate comparison between two EEG 
analysis techniques: period analysis and fast Fourier transform. 
Electroencephalogr Clin Neurophysiol 52: 656-658, 1981. 
 
Porkka-Heiskanen T, Strecker RE, McCarley RW. Brain site-specificity of extracellular 
adenosine concentration changes during sleep deprivation and spontaneous sleep: 
an in vivo microdialysis study. Neuroscience 99: 507-517, 2000. 
 
Ribeiro JA, Sebastiao AM, de Mendonca A. Adenosine receptors in the nervous system: 
pathophysiological implications. Prog Neurobiol 68: 377-392, 2002. 
 
Robert C. Knockout mice: advantages and limitations for biological modeling. 
Definitions, principles and examples. Ann Dermatol Venereol 125: 946-947, 
1998. 
 
Robinson TE, Justice JB, Microdialysis in the Neurosciences. (Elsevier, Amsterdam ; 
New York, 1991). 
 
Sakai M, Fukuyama H, Sato K, Kudoh I. Effects of fentanyl on acetylcholine release 
from hippocampus and righting reflex in rat: an in vivo brain microdialysis study. 
Masui 51: 118-123, 2002. 
 
Sakamoto KM. Knocking down human disease: potential uses of RNA interference in 
research and gene therapy. Pediatr Res 55: 912-913, 2004. 
 
Sarter M, Bruno JP. Cognitive functions of cortical acetylcholine: toward a unifying 
hypothesis. Brain Res Brain Res Rev 23: 28-46, 1997. 
 
Sarter M, Gehring WJ, Kozak R. More attention must be paid: the neurobiology of 
attentional effort. Brain Res Rev 51: 145-160, 2006. 
 
Segerdahl M, Ekblom A, Sandelin K, Wickman M, Sollevi A. Peroperative adenosine 
infusion reduces the requirements for isoflurane and postoperative analgesics. 
Anesth Analg 80: 1145-1149, 1995. 
 
   
 24 
Segerdahl M, Persson E, Ekblom A, Sollevi A. Peroperative adenosine infusion reduces 
isoflurane concentrations during general anesthesia for shoulder surgery. Acta 
Anaesthesiol Scand 40: 792-797, 1996. 
 
Semba K, The Mesopontine Cholinergic System: A Dual Role in REM Sleep and 
Wakefulness In: Handbook of Behavioral State Control: Cellular and Molecular 
Mechanisms, edited by R. Lydic and HA. Baghdoyan (CRC Press LLC, Boca 
Raton, 1999), pp. 161-180. 
 
Shichino T, Murakawa M, Adachi T, Nakao S, Shinomura T, Kurata J, Mori K. Effects of 
isoflurane on in vivo release of acetylcholine in the rat cerebral cortex and 
striatum. Acta Anaesthesiol Scand 41: 1335-1340, 1997. 
 
Sitaram N, Wyatt RJ, Dawson S, Gillin JC. REM sleep induction by physostigmine 
infusion during sleep. Science 191: 1281-1283, 1976. 
 
Stenberg D, Litonius E, Halldner L, Johansson B, Fredholm BB, Porkka-Heiskanen T. 
Sleep and its homeostatic regulation in mice lacking the adenosine A1 receptor. J 
Sleep Res 12: 283-290, 2003. 
 
Stickgold R, Hobson JA, Fosse R, Fosse M. Sleep, learning, and dreams: off-line 
memory reprocessing. Science 294: 1052-1057, 2001. 
 
Straw RN, Mitchell CL. A comparison of the effects of phenobarbital and pentobarbital 
on motor cortical threshold and righting reflex response in the cat. J Pharmacol 
Exp Ther 156: 598-601, 1967. 
 
Subasi A. Application of classical and model-based spectral methods to describe the state 
of alertness in EEG. J Med Syst 29: 473-486, 2005. 
 
Sussman P, Moffitt A, Hoffmann R, Wells R, Shearer J. The description of structural and 
temporal characteristics of tonic electrophysiological activity during sleep. 
Waking Sleeping 3: 279-290, 1979. 
 
Tas PW, Eisemann C, Roewer N. The volatile anesthetic isoflurane suppresses 
spontaneous calcium oscillations in vitro in rat hippocampal neurons by activation 
of adenosine A1 receptors. Neurosci Lett 338: 229-232, 2003. 
 
Thomas M, Sing H, Belenky G, Holcomb H, Mayberg H, Dannals R, Wagner H, Thorne 
D, Popp K, Rowland L, Welsh A, Balwinski S, Redmond D. Neural basis of 
alertness and cognitive performance impairments during sleepiness. I. Effects of 
24 h of sleep deprivation on waking human regional brain activity. J Sleep Res 9: 
335-352, 2000. 
 
   
 25 
Tung A, Herrera S, Szafran MJ, Kasza K, Mendelson WB. Effect of sleep deprivation on 
righting reflex in the rat is partially reversed by administration of adenosine A1 
and A2 receptor antagonists. Anesthesiology 102: 1158-1164, 2005. 
 
Urade Y, Eguchi N, Qu WM, Sakata M, Huang ZL, Chen JF, Schwarzschild MA, Fink 
JS, Hayaishi O. Sleep regulation in adenosine A2A receptor-deficient mice. 
Neurology 61: S94-S96, 2003. 
 
Van Dort CJ, Baghdoyan HA, Lydic R. Dialysis administration of the adenosine A1 
receptor agonist N6-p-sulfophenyladenosine into the prefrontal cortex of 
C57BL/6J mouse decreases prefrontal cortex acetylcholine release and delays 
anesthesia wake-up time. Sleep (Abstract Suppl) 29: 0010, 2006a. 
 
Van Dort CJ, Baghdoyan HA, Lydic R. Microdialysis delivery of caffeine or an 
adenosine A1 receptor antagonist to the prefrontal cortex (PFC) of C57BL/6J 
mouse decreases anesthesia wake-up time and increases PFC acetylcholine (ACh) 
release. Soc. for Neurosci. Program No. 157.14, 2006b. 
 
Van Dort CJ, Baghdoyan HA, Lydic R. Microdialysis delivery of an adenosine A2A 
receptor agonist to the prefrontal cortex of C57BL/6J mouse decreases anesthesia 
wake-up time and increases acetylcholine release. Sleep (Abstract Suppl) 30: 
0001, 2007a. 
 
Van Dort CJ, Baghdoyan HA, Lydic R. Microinjection of an adenosine A1 receptor 
antagonist into the prefrontal cortex of C57BL/6J (B6) mouse increases 
wakefulness and decreases non-rapid eye movement (NREM) sleep. Soc. for 
Neurosci. Program No. 771.1, 2007b. 
 
Vazquez J, Baghdoyan HA. Basal forebrain acetylcholine release during REM sleep is 
significantly greater than during waking. Am J Physiol Regul Integr Comp Physiol 
280: R598-601, 2001. 
 
Violet JM, Downie DL, Nakisa RC, Lieb WR, Franks NP. Differential sensitivities of 
mammalian neuronal and muscle nicotinic acetylcholine receptors to general 
anesthetics. Anesthesiology 86: 866-874, 1997. 
 
Wang H, Shimizu E, Tang YP, Cho M, Kyin M, Zuo W, Robinson DA, Alaimo PJ, 
Zhang C, Morimoto H, Zhuo M, Feng R, Shokat KM, Tsien JZ. Inducible protein 
knockout reveals temporal requirement of CaMKII reactivation for memory 
consolidation in the brain. Proc Natl Acad Sci U S A 100: 4287-4292, 2003. 
 
Watson CJ, Venton BJ, Kennedy RT. In vivo measurements of neurotransmitters by 
microdialysis sampling. Anal Chem 78: 1391-1399, 2006. 
 
   
 26 
Webster HH, Jones BE. Neurotoxic lesions of the dorsolateral pontomesencephalic 
tegmentum-cholinergic cell area in the cat. II. Effects upon sleep-waking states. 
Brain Res 458: 285-302, 1988. 
 
Yamashita M, Mori T, Nagata K, Yeh JZ, Narahashi T. Isoflurane modulation of 
neuronal nicotinic acetylcholine receptors expressed in human embryonic kidney 
cells. Anesthesiology 102: 76-84, 2005. 
 
Yanik G, Radulovacki M. REM sleep deprivation up-regulates adenosine A1 receptors. 
Brain Res 402: 362-364, 1987. 
 
Yu AJ, Dayan P. Acetylcholine in cortical inference. Neural Netw 15: 719-730, 2002. 
 
Yu W, Cheng Q, Feng J, Li F. Microdialysis for pharmacokinetic-pharmacodynamic 
studies. Pharmazie 62: 883-891, 2007. 
 
Zhang L, Samet J, Caffo B, Bankman I, Punjabi NM. Power spectral analysis of EEG 










ADENOSINE A1 AND A2A RECEPTORS IN MOUSE PREFRONTAL CORTEX 
MODULATE ACETYLCHOLINE RELEASE AND BEHAVIORAL AROUSAL 
 
SUMMARY 
During prolonged intervals of wakefulness brain adenosine levels rise within the 
basal forebrain and cortex.  The view that adenosine promotes sleep is supported by the 
corollary that N-methylated xanthines such as caffeine increase brain and behavioral 
arousal by blocking adenosine receptors.  The four subtypes of adenosine receptors are 
distributed heterogeneously throughout the brain, yet the neurotransmitter systems and 
brain regions through which adenosine receptor blockade causes arousal are incompletely 
understood.  The prefrontal cortex contributes to the regulation of sleep and wakefulness.   
This study used in vivo microdialysis to quantify prefrontal cortex acetylcholine release 
with simultaneous recording of the cortical electroencephalogram and time to waking 
after anesthesia.  In additional experiments, sleep and wakefulness were quantified after 
microinjection of an adenosine A1 receptor antagonist into the prefrontal cortex.  This 
chapter reports the results from Aims 1 and 2 demonstrating that adenosine A1 and A2A 
receptors in the prefrontal cortex modulate cortical acetylcholine release, behavioral 
arousal, electroencephalographic delta power, and sleep.  The results provide novel 
evidence that adenosine A1 receptors within the prefrontal cortex comprise part of a 
descending system that inhibits wakefulness. 
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INTRODUCTION 
States of electroencephalographic (EEG) and behavioral arousal are modulated by 
adenosinergic and cholinergic neurotransmission (Steriade and McCarley, 2005).  During 
prolonged intervals of wakefulness, adenosine levels increase within the basal forebrain 
and cortex (Benington and Heller, 1995, Huston et al., 1996, Porkka-Heiskanen et al., 
2000, Radulovacki, 2005).  This rise in adenosine inhibits sub-cortical cholinergic 
neurons known to promote arousal (Basheer et al., 2004, Porkka-Heiskanen et al., 2002).  
Caffeine, the most widely used psychoactive drug (Fredholm et al., 1999), is an 
adenosine A1 and A2A receptor antagonist but the mechanisms through which caffeine 
promotes behavioral arousal are incompletely understood. 
There is good agreement that adenosine A1 and A2A receptors in the brainstem of 
mouse (Coleman et al., 2006), rat (Marks et al., 2003), and cat (Tanase et al., 2003) 
contribute to the regulation of arousal.  The finding that systemically administered 
caffeine increased wakefulness in adenosine A1, but not A2A, receptor knockout mice was 
interpreted to demonstrate that caffeine promotes wakefulness by antagonizing adenosine 
A2A but not A1 receptors (Huang et al., 2005).  No studies have determined whether 
cortical adenosine A1 and/or A2A receptors modulate arousal in wild-type mice. 
The prefrontal cortex contributes to arousal state control in humans (Muzur et al., 2002) 
and modulates EEG activation in C57BL/6J (B6) mouse (Douglas et al., 2002).  The 
present study tested the hypothesis that adenosine A1 and A2A receptors in the prefrontal 
cortex of B6 mouse modulate cortical acetylcholine (ACh) release, behavioral arousal, 
EEG delta power, and sleep.  Adenosine A1 and A2A receptor agonists and antagonists 
were delivered by microdialysis to the prefrontal cortex while measuring prefrontal 
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cortex ACh release, EEG delta power, and time required to resume wakefulness after 
anesthesia.  Finally, this study determined whether microinjecting an adenosine A1 
receptor antagonist into the prefrontal cortex increases wakefulness and decreases sleep. 
 
MATERIALS AND METHODS 
Overview of Experimental Design 
All experiments adhered to the Public Health Service Policy on Humane Use and 
Care of Laboratory Animals (NIH Publication 80-23, National Academy of Sciences 
Press, Washington, DC, 1996) and were reviewed and approved by the University of 
Michigan Committee on Use and Care of Animals.  Experiments used adult male 
C57BL/6J (B6) mice (n=101; Jackson Laboratory, Bar Harbor, ME, USA).  Mice had ad 
libitum access to food and water.  Each mouse was used for only one dialysis experiment, 
and only one drug concentration was tested per mouse. 
The time course of the dialysis experiments and collection and quantification of 
ACh from the frontal association area (FrA) is schematized by Figure 2.1A. The FrA is 
the mouse homologue of the prefrontal cortex (Fuster, 2001).  These studies measured 
prefrontal cortex ACh release during isoflurane anesthesia.  Control ACh release was 
determined during dialysis with Ringer’s prior to dialysis delivery of adenosine A1 and 
A2A receptor agonists and antagonists.  An additional dependent measure included the 
time (min) required for resumption of righting after offset of isoflurane anesthesia.  A 
second set of experiments conducted during isoflurane anesthesia recorded the cortical 
EEG while measuring prefrontal cortex ACh release and time to waking after anesthesia.  
The dependent measures of time to waking after anesthesia (Tung et al., 2002, Tung et 
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al., 2005), ACh release in the prefrontal cortex (Kozak et al., 2006), and decreased EEG 
delta power (Douglas et al., 2002) are accepted indicators of behavioral arousal.  A third 
set of experiments was conducted using intact, unanesthetized mice implanted with a 
guide tube aimed for the prefrontal cortex and with EEG and EMG electrodes, making it 
possible to record states of wakefulness, non-rapid eye movement (NREM) sleep, and 
rapid eye movement (REM) sleep. 
Experimental Procedures 
Microdialysis and high performance liquid chromatography with 
electrochemical detection (HPLC/EC).  Mice were anesthetized with 2.0% isoflurane in 
O2 and placed in a Kopf Model 962 small animal stereotaxic instrument with a Kopf 
Model 923-B mouse anesthesia mask (David Kopf Instruments, Tujunga, CA).  Delivered 
isoflurane concentration was measured using a Cardiocap/5 monitor (Datex-Ohmeda, 
Madison, WI) and decreased to 1.6% for the surgery.  Core body temperature was 
monitored and held constant between 36.5-37.5°C throughout the experiment.  A skull 
craniotomy of 1 mm diameter was made at stereotaxic coordinates 3.0 mm anterior to 
bregma and 1.6 mm lateral to the midline (Paxinos and Franklin, 2001) for placement of 
a CMA/7 dialysis probe (6 kDa cutoff; 1.0 mm length, 0.24 mm diameter cuprophane 
membrane; CMA/Microdialysis, Stockholm, Sweden) in the prefrontal cortex (Fig. 1B).  
After the craniotomy was made, delivered isoflurane concentration was reduced and 
maintained at 1.3%, corresponding to the EC50 or minimum alveolar concentration (1 
MAC) for B6 mouse (Sonner et al., 1999).   
The microdialysis probe was perfused continuously (2 µl/min) with Ringer's 
solution (control) comprised of 147 mM NaCl, 2.4 mM CaCl2, 4 mM KCl, and 10 µM 
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neostigmine.  Salts used in the Ringer’s solution were purchased from Fisher Scientific 
(Pittsburgh, PA).  Drugs delivered to the prefrontal cortex by microdialysis included the 
adenosine A2A receptor agonist 2-p-(2-Carboxyethyl)phenethylamino-5′-N-
ethylcarboxamidoadenosine hydrochloride (CGS 21680; CGS), the adenosine A2A 
receptor antagonist 4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-
ylamino]ethyl)phenol (ZM 241385; ZM), the adenosine A1 receptor agonist N6-p-
Sulfophenyladenosine sodium salt (SPA), and the adenosine A1 receptor antagonist 8-
Cyclopentyl-1,3-dipropylxanthine (DPCPX).  Prefrontal cortex ACh was also measured 
before and during delivery of the adenosine receptor antagonist caffeine.  DPCPX and 
ZM were dissolved in dimethylsulfoxide (DMSO) and diluted in Ringer’s to a final 
DMSO concentration of 1.0% and 0.07% respectively.  CMA/7 dialysis probes are 
estimated to deliver about 5% of any given drug concentration.  Thus, estimated drug 
concentrations that significantly changed the dependent measures ranged from 500 nM to 
50 µM.  SPA, CGS, DPCPX, caffeine, and neostigmine bromide were purchased from 
Sigma-Aldrich (St. Louis, MO).   ZM was purchased from Tocris (Ellisville, MO).  
A CMA/110 liquid switch was used to dialyze with Ringer’s followed by Ringer’s 
containing drug (Fig. 1A).  Dialysis samples were collected every 12.5 min.  Six samples 
were collected during dialysis with Ringer’s (control) then six samples were collected 
during dialysis with drug.  Each 25 µl dialysis sample was injected into a HPLC/EC 
system (Bioanalytical Systems, (BAS), West Lafeyette, IN).  The sample was carried 
through the system in 50 mM Na2HPO4 mobile phase (pH 8.5) at a flow rate of 1 ml/min.  
ACh and choline were separated by an analytical column and then broken down into 
hydrogen peroxide by an immobilized enzyme reaction column.  The hydrogen peroxide 
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was detected by a platinum electrode (0.5 V applied potential) in reference to an 
Ag+/AgCl electrode.   Chromgraph software (Bioanalytical Systems Inc.) was used to 
digitize and quantify the resulting chromatograms (Fig. 1C) compared to a series of ACh 
standards.  The percentage of a known ACh solution recovered by the probe was 
determined before and after every experiment.  If the pre-and post-experiment probe 
recoveries were significantly different by t-test, the data from that experiment were 
discarded. 
Time to Resumption of Wakefulness after Anesthesia.  At the end of the 
experiment when microdialysis sample collection was completed, the dialysis probe was 
removed, the scalp incision was closed, and anesthesia was discontinued.  Mice were 
removed from the stereotaxic frame and placed in dorsal recumbency under a heat lamp.  
The time to righting and resumption of normal weight-bearing posture was recorded.  The 
resumption of righting response provides an established measure of the time for the onset 
of wakefulness after cessation of anesthesia (Bignall, 1974, DeMarco et al., 2004, Kelz et 
al., 2008, Kubota et al., 1999, Tung et al., 2002, Tung et al., 2005). 
EEG Recording and Power Spectral Analysis.  Electrodes for recording the 
EEG were constructed from 0.13 mm diameter stainless steel wire (California Fine Wire, 
Grover City, CA) and were implanted above the cortex, contralateral to the microdialysis 
probe.  The stereotaxic coordinates for the 2 EEG electrodes were 2.8 mm anterior to 
bregma and 2.4 mm posterior to bregma with both at -1.5 mm lateral to the midline.  The 
EEG was recorded during dialysis with Ringer’s (control; 75 min) and during dialysis 
with drug (75 min).  The EEG signal was amplified and filtered at 0.3 and 30 Hz using a 
Grass (West Warwick, RI) Model P511K amplifier.  The amplified and filtered EEG was 
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digitized and recorded using Spike2 (Cambridge Electronic Design, Cambridge, UK) 
software at a sampling rate of 128 Hz.  Fast Fourier transform (FFT) analysis was used to 
compute EEG power (V2) in 0.5 Hz increments for EEG frequencies ranging from 0.5 to 
25.0 Hz.  Sample bins were 10 s in duration.  During each experiment the 10 s bins were 
sampled every 250 s and EEG power was computed for 18 bins during Ringer’s dialysis 
and 18 bins during dialysis drug delivery.  
Recording Sleep in the Freely Behaving Mouse.  Adult male B6 mice were 
stereotaxically implanted under isoflurane anesthesia with EEG and EMG recording 
electrodes and a guide tube aimed for the prefrontal cortex as described above.  The guide 
tube was placed at a 45 degree angle at coordinates 3 mm anterior to bregma and 0.5 mm 
lateral to the midline (Paxinos and Franklin, 2001).  The EEG recording electrodes were 
constructed as described above and the EMG recording electrodes were constructed from 
AS632 biomed wire (Cooner Wire Company, Chatsworth, CA).  The guide tube, two 
stainless steel anchor screws (Small Parts Inc., Miami Lakes, FL), EEG and EMG 
electrodes, and a plastic pedestal (Plastics One, Roanoke, VA) containing the electrodes 
were adhered to the skull using dental acrylic.  The mice were allowed to recover for one 
week and conditioned to handling and being placed in a Plexiglas recording chamber 
(BAS Raturn system; Bioanalytical Systems Inc., West Lafayette, IN).   
The day before the experiment, mice were placed in the recording chamber 
between 16:00 and 17:00 h and left overnight.  On the day of the experiment between 
9:00 and 10:00 h, a 50 nL microinjection of 100 µM (1.5 ng) DPCPX or saline + 1% 
DMSO (vehicle) was performed followed by a 2 h recording of sleep and wakefulness.  
The EEG and EMG signals were amplified with a Grass Instruments model 15RXi 
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amplifier (West Warwick, RI).  Signals were filtered (EEG: 0.1-30 Hz; EMG: 10-100 
Hz), digitized at 128 Hz, and recorded using Icelus Acquisition software (Opp, 1998).  
Each mouse received 2 microinjections that were separated by 1 week.  States of 
wakefulness, NREM sleep, and REM sleep were quantified in 10 s bins.  The EEG power 
spectra were quantified using FFT analysis.   
Statistics 
ACh release was expressed as percent of ACh measured during dialysis with 
Ringer’s (control condition).  Drug main-effects on prefrontal cortex ACh release and 
time to waking after anesthesia were analyzed using one-way analysis of variance 
(ANOVA).  Post-hoc analyses included Dunnett’s statistic, Tukey-Kramer multiple 
comparisons test, and Student's t-test (GBStatTM v6.5.6, Dynamic Microsystems, Inc., 
Silver Spring, MD).  Drug effects on EEG power were evaluated using two-way repeated 
measures ANOVA on treatment, frequency and the interaction, and a post hoc analysis to 
test the effect of treatment on a given frequency (SAS v9.1.3, SAS Institute Inc., Cary, 
NC).  Non-linear regression analysis of the concentration response data provided 
coefficients of determination (r2) for each drug (GraphPad Prism software v4.0a for 
Macintosh, GraphPad Software Inc., San Diego, CA).  Sleep and wake data were 
analyzed using Student’s t-test.  Data are reported as mean ± standard error of the mean 
(SEM).  A probability value of P ≤ 0.05 was considered to be statistically significant. 
Histology 
Seven days after microdialysis experiments and 3 days after microinjection 
experiments, mice were deeply anesthetized and decapitated.  The brains were removed, 
frozen, and coronally sectioned (40 µm thick).  The sections were fixed with hot (80°C) 
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paraformaldehyde vapor and stained with cresyl violet.  The location of a glial scar 
caused by the microdialysis probe or microinjector was determined by comparing stained 
sections with a mouse brain atlas (Paxinos and Franklin, 2001).  Results were included in 
the group data only for experiments in which histology confirmed that the microdialysis 
probe or microinjector was placed in the prefrontal cortex. 
 
RESULTS 
Figure 2.1A illustrates the within-subjects design used for the microdialysis 
experiments.  ACh release was quantified during 75 min of dialysis with Ringer’s 
(control) followed by an additional 75 min of dialysis with Ringer’s (negative control) or 
Ringer’s containing drug.  Results of the negative control experiments confirmed that 
ACh release was stable during 150 min of isoflurane anesthesia.  One-way ANOVA 
revealed no significant difference in total anesthesia time (mean ± SEM = 284 ± 2 min) 
across all microdialysis experiments.  The results summarize data obtained from 101 
mice.  Post-experiment histological analysis using the B6 mouse brain atlas (Paxinos and 
Franklin, 2001) confirmed that all microdialysis and microinjection sites were within the 
FrA of the prefrontal cortex. 




Figure 2.1.  Microdialysis experimental design.  (A) Schematic time-line of 
microdialysis experiments.  The top row outlines the experimental manipulations and the 
bottom row indicates when the dependent measures were obtained.  (B) The coronal 
diagram modified from a mouse brain atlas (Paxinos and Franklin, 2001) illustrates 
placement of a microdialysis probe in the frontal association area (FrA), mouse 
homologue of the prefrontal cortex (Fuster, 2001).  The dialysis probe membrane (1 mm 
length, 0.24 mm diameter) is drawn to scale and EEG recording electrodes are 
schematized above the contralateral prefrontal cortex.  (C) The representative 
chromatogram shows an acetylcholine (ACh) peak obtained by microdialysis of the 
prefrontal cortex. 
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An adenosine A2A receptor agonist increased waking phenotypes.   
The first set of studies was designed to determine whether microdialysis delivery 
of the adenosine A2A receptor agonist CGS to the prefrontal cortex increased waking 
phenotypes.  For these mice (n = 21) waking phenotypes included increased cortical ACh 
release, decreased time to waking after anesthesia, and cortical EEG activation.  CGS 
caused a significant drug main effect on ACh release within the prefrontal cortex (F(5,12) = 
12.8, P = 1.9 x 10-4) (Fig. 2.2A) and time required for resumption of wakefulness after 
isoflurane anesthesia (F(5,12) = 6.4, P = 0.0042) (Fig. 2.2B).  The right-most point in Fig. 
2.2A and B (10 + ZM) shows that CGS (10 µM) coadministered with the adenosine A2A 
receptor antagonist ZM (0.1 µM) blocked the effects of CGS on ACh release and 
anesthesia recovery time.  Figure 2.2C illustrates that CGS also decreased delta power in 
the cortical EEG.  FFT analyses confirmed a decrease in EEG delta power (0.5 to 4 Hz) 
caused by CGS.  Two-way repeated measures ANOVA revealed no frequency by drug 
interaction but post hoc analyses comparing the means at each frequency between 
treatments revealed that delta power from 0.5 to 1.0 Hz was significantly reduced by 
CGS.  The ANOVA included 8 frequency conditions (0.5 to 4.0 Hz every 0.5 Hz) and 2 
treatment conditions (Ringer’s or CGS). 
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Figure 2.2.  Microdialysis delivery of CGS to the prefrontal cortex increased all 
measures of arousal.  CGS caused a concentration dependent increase in ACh release (A), 
decrease in time to waking after anesthesia (B), and decrease in EEG delta power (C).  
Each point in A and B plots data from 3 mice.  Post-hoc Dunnett’s statistic showed that 
CGS (10 µM) significantly (* P < 0.01) increased ACh release and decreased time to 
righting after anesthesia, and that coadministration of CGS plus the antagonist (10 + ZM) 
blocked these effects.  Comparison of the two functions shown in A and B by regression 
analysis indicates that ACh release in the prefrontal cortex accounted for 99.9% of the 
variance in time to waking after anesthesia.  The EEG power spectra in C represent an 
average from 3 additional mice.  The inset in C shows representative 10 s EEG 
recordings during dialysis with Ringer’s or Ringer’s containing CGS.  The black bar 
(lower left of C) indicates significantly different EEG delta frequencies between Ringer’s 
and CGS dialysis.   
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Waking phenotypes were decreased by an adenosine A1 receptor agonist. 
Additional experiments in another group of mice (n = 21) determined whether 
microdialysis delivery of the adenosine A1 receptor agonist SPA to the prefrontal cortex 
reduced ACh release and arousal.  SPA caused a significant drug main effect on 
prefrontal cortex ACh release (F(6,14) = 25.0, P = 1.03 x 10-6) (Fig. 2.3A) and the amount 
of time required for resumption of waking after anesthesia (F(6,14) = 46.5, P = 1.8 x 10-8) 
(Fig. 2.3B).  Coadministration of the adenosine A1 receptor antagonist DPCPX (100 µM) 
with SPA (10 mM) blocked the effects of SPA (10 + DPCPX in Fig. 2.3A and B).  Figure 
2.3C illustrates that SPA increased EEG delta power.  Two-way repeated measures 
ANOVA identified a significant frequency by drug interaction (F(7,14) = 9.3, P = 0.0002) 
and post hoc analyses revealed that SPA significantly increased EEG delta power in the 
0.5 to 2.5 Hz band. 
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Figure 2.3.  Dialysis administration of SPA to the prefrontal cortex decreased dependent 
measures of arousal.  SPA caused a concentration dependent decrease in ACh release in 
the prefrontal cortex (A) and an increase in time required for resumption of wakefulness 
after anesthesia (B).  Asterisks (* P < 0.05, ** P < 0.01) indicate concentrations of SPA 
that caused a significant difference compared to Ringer’s control (0 mM SPA) by post 
hoc Dunnett’s statistic.  Coadministration of SPA plus the antagonist (10 + DPCPX) 
blocked the effects of SPA on both ACh release and time to resumption of righting.  
Comparison by regression analysis of data shown in A and B indicate that ACh release 
accounted for 90.2% of the variance in wake-up time.  Each point in A and B summarizes 
results from 3 mice.  C illustrates EEG power spectra averaged for 3 additional mice 
during dialysis with Ringer’s (control) or Ringer’s containing 1 mM SPA.  The inset (C) 
shows two 10 s EEG recordings and the black bar indicates the significant SPA-induced 
increase in the 0 to 4 Hz delta range.   
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Caffeine and an adenosine A1 receptor antagonist but not an adenosine A2A receptor 
antagonist enhanced waking phenotypes.  
Having demonstrated that exogenous adenosine A1 and A2A receptor agonists 
delivered to the prefrontal cortex alter waking phenotypes, 42 additional mice were used 
to determine whether endogenous adenosine acting at adenosine A1 and/or A2A receptors 
modulates the same arousal phenotypes.  Dialysis delivery of caffeine caused a 
significant, concentration dependent increase in ACh release within the prefrontal cortex 
during anesthesia (F(4,10) = 3.5, P = 0.049) (Fig. 2.4A) and decrease in the time required 
for resumption of waking after anesthesia (F(4,10) = 6.9, P = 0.0061) (Fig. 2.4B).  Dialysis 
delivery of the adenosine A1 receptor antagonist DPCPX also caused a significant, 
concentration dependent increase in prefrontal cortex ACh release (F(5,12) = 201.7, P = 3.8 
x 10-11) (Fig. 2.4A) and a significant, concentration dependent decrease in time required 
for resumption of waking after anesthesia (F(5,12) = 8.2, P = 0.0014) (Fig. 2.4B).  In 
contrast, dialysis delivery of five concentrations of the adenosine A2A receptor antagonist 
ZM to the prefrontal cortex did not alter prefrontal cortex ACh release (Fig. 2.4A) or time 
to waking after anesthesia (Fig. 2.4B).  In order to maintain selectivity for the A2A 
receptor (Linden et al., 1999, Lopes et al., 1999), greater concentrations of ZM were not 
tested. 
 
Adenosine A1 receptors in prefrontal cortex modulate ACh release and arousal: 
Efficacy and potency comparisons. 
Derivation of the concentration response data for selective antagonist of the 
adenosine A1 receptor (DPCPX), the adenosine A2A receptor (ZM), and the mixed 
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antagonist (caffeine) made it possible to gain insight into their relative efficacy and 
potency for altering ACh release and arousal.  Figure 2.4A shows that dialysis delivery of 
DPCPX produced the greatest increase in ACh release, ZM did not alter ACh release, and 
caffeine caused a significant increase in ACh release.  The percent of variance in ACh 
release accounted for by the three antagonists was 100% for caffeine, 99% for DPCPX, 
and 30% for ZM.  Figure 2.4B suggests that DPCPX and caffeine are equally efficacious 
in shortening the time required for resumption of wakefulness, and DPCPX is more 
potent than caffeine.  Across the range of concentrations examined, ZM did not shorten 
time to resumption of righting.  The percent of variance in anesthesia recovery time 
accounted for by the three antagonists was 97% for DPCPX, 89% for caffeine, and 15% 
for ZM. 
 
Caffeine and an adenosine A1 receptor antagonist but not an adenosine A2A receptor 
antagonist decreased EEG delta power.  
Caffeine significantly decreased EEG delta power (Fig. 2.5A).  Two-way repeated 
measures ANOVA revealed no frequency by drug interaction but post hoc analyses 
comparing the means at each frequency between treatments indicated that caffeine 
depressed EEG power at 1.0 Hz.  The DPCPX-induced decrease in EEG delta power is 
shown in Fig. 2.5B.  Two-way repeated measures ANOVA revealed significant 
frequency by drug interaction (F(7, 14) = 43.2, P < 0.0001) and post hoc analyses showed 
that DPCPX depressed EEG power from 0.5 to 3.5 Hz.   Figure 2.5C illustrates that the 
adenosine A2A receptor antagonist ZM did not alter EEG delta power. 




Figure 2.4.  Caffeine and DPCPX promote arousal.  Caffeine and DPCPX (A) increased 
prefrontal cortex ACh release and (B) decreased time to waking after anesthesia.  Each 
point in A and B summarizes mean ± standard error of the mean (SEM) from 3 mice.  
Post-hoc Dunnett’s analysis identified concentrations of caffeine and DPCPX that caused 
a significant (* P < 0.05, ** P < 0.01) change from Ringer’s control.  Application of 
regression analyses to compare ACh release (A) and time to righting (B) revealed that 
ACh release in the prefrontal cortex accounted for 93% of the variance in time to righting 
after anesthesia for caffeine, 92% for DPCPX, and 0.4% for ZM.  Dialysis administration 
of ZM to the prefrontal cortex did not alter either dependent measure of arousal.   
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Figure 2.5.  Power spectral analysis of the cortical EEG revealed that caffeine (A) and 
DPCPX (B) significantly decreased EEG delta power.  Dialysis delivery of ZM (C) did 
not decrease EEG delta power.  The insets show 10 s EEG recordings from the same 
mouse during dialysis with Ringer’s or Ringer’s containing drug.  Black bars (lower left 
of A and B) indicate delta frequency bands that showed significantly decreased power 
during dialysis with caffeine and DPCPX.  Each graph represents data obtained from 3 
mice.   
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Microinjecting an adenosine A1 receptor antagonist into the prefrontal cortex of 
unanesthetized B6 mice increased wakefulness and decreased NREM sleep. 
The foregoing results encouraged a final set of experiments using intact, 
unanesthetized B6 mice (n = 8) to determine whether prefrontal cortex administration of 
the adenosine A1 receptor antagonist DPCPX altered sleep and wakefulness.  Compared 
to microinjection of saline (control), (Fig. 2.6A) DPCPX increased wakefulness by 
25.0% (t(14) = 13.1, P = 1.5 x 10-9) and decreased NREM sleep by 40.3% (t(14) = 13.4, P = 
1.1 x 10-9).  Figure 2.6B, C, and D summarize the averaged EEG power spectra during 
wakefulness, NREM sleep, and REM sleep.  Insets show representative EEG and EMG 
recordings from the same mouse after microinjection of DPCPX.  Wakefulness was 
characterized by a mixed frequency EEG and high amplitude EMG.  NREM sleep was 
characterized by high delta power (0.5 - 4 Hz) in the EEG and a lower amplitude EMG.  
REM sleep was characterized by a high theta power (5 - 8 Hz) in the EEG and a low 
amplitude EMG.  Figure 2.6B, C, and D demonstrate that EEG power spectra were not 
different following microinjection of saline or DPCPX.  Sleep architecture was normal 
after microinjection of DPCPX, and REM sleep always followed NREM sleep.   
 




Figure 2.6.  Microinjection of the adenosine A1 receptor antagonist DPCPX into the 
prefrontal cortex caused a significant (* P < 0.0001 by Student’s t-test) (A) increase in 
wakefulness and decrease in NREM sleep.  The EEG power spectra did not differ 
between saline and DPCPX for (B) waking, (C) NREM sleep, or (D) REM sleep.  EEG 
data were analyzed in 0.5 Hz increments and represent the average of 8 mice.  The insets 
show 10 s EEG and EMG recordings after microinjection of DPCPX.   
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DISCUSSION 
Two novel findings emerged from this study.  First, microdialysis delivery of 
adenosinergic agonists and antagonists to the prefrontal cortex showed that adenosine 
receptors in the prefrontal cortex exert descending modulation of behavioral arousal.  
Top-down modulation from prefrontal cortex to basal forebrain is important for 
cholinergically mediated focused attention (Sarter et al., 2006).  Antagonism of adenosine 
A1 receptors with DPCPX and caffeine suggests the possibility that adenosine in the 
prefrontal cortex can also inhibit caudal brain centers that generate behavioral arousal.  
Second, the results indicate a definitive role for prefrontal cortex adenosine A1 receptors 
in the modulation of ACh release, behavioral arousal, EEG delta power, and sleep.  
Previous studies of adenosine A1 receptor knockout mice suggested that caffeine 
modulates arousal solely via adenosine A2A receptors (Huang et al., 2005).  As discussed 
below, the present data show that in the prefrontal cortex, endogenous adenosine acting at 
adenosine A1 receptors decreases arousal, and that caffeine blocks the effects of 
endogenous adenosine on arousal by antagonizing prefrontal cortex adenosine A1 
receptors.  
 
Adenosine A1 and A2A receptor agonists had opposing effects on waking phenotypes.  
Dialysis administration of the adenosine A2A receptor agonist CGS caused a 
concentration dependent increase in ACh release (Fig. 2.2A) and decrease in the time to 
waking after anesthesia (Fig. 2.2B).  The increase in prefrontal cortex ACh release 
parallels findings in the pontine reticular formation of B6 mouse where dialysis delivery 
of similar concentrations of CGS also caused an increase in ACh release (Coleman et al., 
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2006).  This same study found that CGS caused a biphasic concentration response curve 
for ACh release by activating adenosine A1 receptors at higher concentrations (Coleman 
et al., 2006, Halldner et al., 2004, Klotz, 2000, Lopes et al., 2004).  In the present study, 
microdialysis with 30 µM CGS caused no change in ACh release or anesthesia recovery 
time, suggesting that at dialysis concentrations greater than 10 µM, CGS loses specificity 
for the A2A receptor and starts to bind the adenosine A1 receptor.  The findings that the 
CGS effects were concentration dependent and blocked by the antagonist ZM (Fig. 2.2A 
and B) support the interpretation that adenosine A2A receptors in the prefrontal cortex 
respond to exogenous agonists by increasing ACh release and behavioral arousal, and 
decreasing EEG slow wave activity.   
Dialysis administration of the adenosine A1 receptor agonist SPA caused a 
concentration dependent decrease in ACh release (Fig. 2.3A) within the prefrontal cortex 
and an increase in time required for resumption of waking after anesthesia (Fig. 2.3B).  
The decrease in ACh release and the increase in time to waking after anesthesia were 
blocked by coadministering the adenosine A1 receptor antagonist DPCPX.  These 
findings are consistent with previous data showing that dialysis delivery of SPA to cat 
pontine reticular formation caused a decrease in ACh release and an increase in the time 
required to awaken after anesthesia (Tanase et al., 2003).  These data demonstrate that 
adenosine A1 receptors in the prefrontal cortex can decrease ACh release, as well as 
behavioral and EEG arousal.   
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Endogenous adenosine in the prefrontal cortex decreases arousal by actions at 
adenosine A1 receptors.      
The adenosine A2A receptor antagonist ZM blocked the CGS-induced 
enhancement of waking phenotypes, but ZM alone did not alter prefrontal cortex ACh 
release (Fig. 2.4A), time to waking after anesthesia (Fig. 2.4B), or EEG delta power (Fig. 
2.5C).  These results suggest that in B6 mouse endogenous adenosine does not alter 
arousal through adenosine A2A receptors in the prefrontal cortex.  In contrast, the 
adenosine A1 receptor antagonist DPCPX caused a significant, concentration dependent 
increase in ACh release within the prefrontal cortex (Fig. 2.4A), decrease in time for 
resumption of waking after anesthesia (Fig. 2.4B), and decreased delta power in the EEG 
(Fig. 2.5B).  The DPCPX data show, for the first time, that behavioral and EEG arousal 
are reduced by endogenous adenosine acting at adenosine A1 receptors in the prefrontal 
cortex of B6 mouse.  This interpretation is also supported by the caffeine data.  Caffeine 
caused a significant, concentration dependent increase in ACh release within the 
prefrontal cortex (Fig. 2.4A), decrease in time to waking after anesthesia (Fig. 2.4B), and 
decreased EEG delta power (Fig. 2.5A).   
The recordings of sleep and wakefulness also demonstrate that adenosine A1 
receptors in the prefrontal cortex contribute to the regulation of EEG and behavioral 
arousal.  Microinjection of the adenosine A1 receptor antagonist DPCPX into the 
prefrontal cortex increased wakefulness and decreased NREM sleep (Fig. 2.6A).  
Following microinjection of saline and DPCPX, the mice exhibited normal behavioral 
phenotypes of grooming and locomotor behavior.  Quantitative EEG analyses (Fig. 2.6B, 
C, and D) revealed no significant differences following saline control and DPCPX 
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microinjections.  Considered together with the microdialysis results, the microinjection 
data indicate that DPCPX enhanced wakefulness and decreased sleep by increasing 
prefrontal cortex ACh release.  Thus, multiple lines of evidence support the interpretation 




The prefrontal cortex contributes to the regulation of sleep and wakefulness 
(Muzur et al., 2002), and the present results show for the first time that adenosine A1 and 
A2A receptors in the prefrontal cortex of B6 mouse modulate behavioral arousal, cortical 
ACh release, EEG delta power, and sleep.  Caffeine is an adenosine A1 and A2A receptor 
antagonist and data from humans and rodents indicate that caffeine promotes arousal by 
enhancing cortical cholinergic transmission.  For example, caffeine enhances 
psychomotor vigilance, in part, by activating the human prefrontal cortex (Higashi et al., 
2004) and systemic administration of caffeine increases ACh release in the prefrontal 
cortex of rat (Acquas et al., 2002).  Attention demanding tasks increase ACh release in 
the prefrontal cortex (Kozak et al., 2006) and morning consumption of caffeine is an 
effective countermeasure for cognitive deficits known to be associated with sleep inertia 
(Van Dongen et al., 2001).  Microdialysis delivery of caffeine, DPCPX, and ZM in the 
present study demonstrates that ACh release in the prefrontal cortex is significantly 
increased by blocking adenosine A1 receptors.  The present results suggest that adenosine 
A1 receptors in the prefrontal cortex activate a descending system that decreases arousal, 
likely via extensive projections to caudal brain regions (Gabbott et al., 2005, Morgane 
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and Mokler, 2006).  The ability of caffeine to antagonize descending pathways that 
inhibit wakefulness comprise one mechanism by which the prefrontal cortex can override 
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ADENOSINE A1 AND A2A RECEPTORS IN MOUSE PREFRONTAL CORTEX 




Prefrontal cortex adenosine receptors modulate cortical acetylcholine release, 
electroencephalographic and behavioral arousal, as well as sleep in the C57BL/6J mouse 
(Van Dort CJ et al., 2008).  These results, and early brain transection studies 
demonstrating that the forebrain is not needed to generate the non-rapid eye movement 
(NREM)/ rapid eye movement (REM) sleep cycle (Jouvet, 1962), suggest that the 
prefrontal cortex modulates arousal states via descending input to caudal arousal control 
centers.  Therefore this study tested the hypothesis that dialysis delivery of adenosine A1 
and A2A receptor agonists and antagonists to the prefrontal cortex of B6 mouse modulates 
pontine reticular formation acetylcholine release.  Results from Aim 3 are reported in this 
Chapter.  Microdialysis delivery of an adenosine A2A receptor agonist to the prefrontal 
cortex increased simultaneously collected pontine reticular formation acetylcholine 
(ACh) release, whereas administering an adenosine A1 receptor agonist decreased pontine 
reticular formation acetylcholine release.  These findings are the first to demonstrate that 
pharmacological manipulation of the prefrontal cortex can alter neurotransmitter release 
in the pontine reticular formation.  The adenosine A1 and A2A receptor antagonist, 
caffeine and an adenosine A1 receptor antagonist delivered by microdialysis to the 
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prefrontal cortex increased pontine reticular formation ACh release.  These data are 
consistent with the interpretation that endogenous adenosine in the prefrontal cortex can 
modulate behavioral arousal states, in part, via a descending pathway that alters 
acetylcholine release in the pontine reticular formation. 
 
INTRODUCTION 
Adenosine promotes sleep and caffeine, the most commonly used psychoactive 
stimulant (Fredholm et al., 1999), promotes wakefulness by antagonizing adenosine A1 
and A2A receptors.  The specific brain regions and receptor subtypes important for the 
regulation of behavioral arousal by adenosine remain incompletely understood.  Data 
support a role for both adenosine A1 (Basheer et al., 2001, Benington et al., 1995, 
Elmenhorst et al., 2007, Yanik and Radulovacki, 1987) and A2A (Huang et al., 2005, 
Urade et al., 2003) receptors in promoting sleep.  Prefrontal cortex adenosine A1 and A2A 
receptors have recently been shown to modulate behavioral arousal, ACh release in the 
prefrontal cortex, and sleep (Van Dort CJ et al., 2008).  Although the prefrontal cortex 
helps regulate wakefulness, early brain transection studies showed that the forebrain is 
not necessary for generating the NREM and REM sleep cycle (Jouvet, 1962).  One 
mechanism through which the prefrontal cortex might alter behavioral arousal is via 
descending input to caudal brain regions known to regulate sleep and wakefulness 
(Steriade and McCarley, 2005).   
Several lines of evidence provide justification for choosing the pontine reticular 
formation as one region through which the prefrontal cortex alters behavioral arousal.  
First, the classic studies of Moruzzi and Magoun (Moruzzi and Magoun, 1949) showed 
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that stimulation of the pontine reticular formation activates the cortex via the ascending 
reticular activating system.  Second, there are projections from the prefrontal cortex to 
the pontine reticular formation in Wistar rat (Allen and Hopkins, 1998, Brodal and 
Bjaalie, 1992).  In addition to neuroanatomical studies, neurochemical data show that 
cholinergic neurotransmission in the pontine reticular formation can alter ACh release in 
the prefrontal cortex (DeMarco et al., 2004).   
Despite the known descending projections from the prefrontal cortex to the 
pontine reticular formation, no previous studies have investigated whether these 
projections modulate neurotransmitter release in the pontine reticular formation.  
Therefore, the present experiments were designed to test the hypothesis that dialysis 
delivery of adenosine A1 and A2A receptor agonists and antagonists to the prefrontal 
cortex of B6 mouse modulates pontine reticular formation acetylcholine release. 
 
MATERIALS AND METHODS 
All experiments adhered to the Public Health Service Policy on Humane Use and 
Care of Laboratory Animals (NIH Publication 80-23, National Academy of Sciences 
Press, Washington, DC, 1996) and were reviewed and approved by the University of 
Michigan Committee on Use and Care of Animals.  Adult male C57BL/6J (B6) mice 
(n=12; Jackson Laboratory, Bar Harbor, ME, USA) were kept under constant 
illumination and had ad libitum access to food and water.  Each mouse was used for only 
one experiment. 
Experimental Procedure.  Figure 3.1 illustrates the experimental design including 
the location of the 2 dialysis probes, drug delivery to the prefrontal cortex, and 
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quantification of ACh release from the pontine reticular formation.  Mice were 
anesthetized with 2.0% isoflurane in O2 and placed in a Kopf Model 962 small animal 
stereotaxic instrument with a Kopf Model 923-B mouse anesthesia mask (David Kopf 
Instruments, Tujunga, CA).  Delivered isoflurane concentration was measured using a 
Cardiocap/5 monitor (Datex-Ohmeda, Madison, WI) and decreased to 1.6% for the 
surgery.  Core body temperature was monitored and held constant between 36.5-37.5°C 
throughout the experiment.  Two craniotomies were made, one at stereotaxic coordinates 
3.0 mm anterior to bregma and 1.6 mm lateral to the midline and a second at 4.72 mm 
posterior to bregma and 0.7 mm lateral to the midline (Paxinos and Franklin, 2001).  
Delivered isoflurane concentration was then reduced and maintained at 1.3%, 
corresponding to the EC50 or minimum alveolar concentration for B6 mouse (Sonner et 
al., 1999).   
In vivo microdialysis and high performance liquid chromatography with 
electrochemical detection (HPLC/EC).  Two CMA/7 dialysis probes (6 kDa cutoff; 1.0 
mm length, 0.24 mm diameter cuprophane membrane; CMA/Microdialysis, Stockholm, 
Sweden) were used for each experiment.  The microdialysis probes were perfused 
continuously (2 µl/min) with Ringer's solution (control) comprised of 147 mM NaCl, 2.4 
mM CaCl2, 4 mM KCl, and 10 µM neostigmine.  Salts used in the Ringer’s solution were 
purchased from Fisher Scientific (Pittsburgh, PA).  Drugs delivered to the prefrontal 
cortex by microdialysis included the adenosine A2A receptor agonist 2-p-(2-
Carboxyethyl)phenethylamino-5′-N-ethylcarboxamidoadenosine hydrochloride (CGS 
21680; CGS), the adenosine A1 receptor agonist N6-p-Sulfophenyladenosine sodium salt 
(SPA), the adenosine A1 receptor antagonist 8-Cyclopentyl-1,3-dipropylxanthine 
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(DPCPX), and the adenosine A1 and A2A receptor antagonist caffeine.  DPCPX was 
dissolved in dimethylsulfoxide (DMSO) and diluted in Ringer’s to a final DMSO 
concentration of 1.0%.  SPA, CGS, DPCPX, caffeine, and neostigmine bromide were 
purchased from Sigma-Aldrich (St. Louis, MO).    
 





Figure 3.1.  Timeline of a microdialysis experiment.  (A) Shows the sequence of events 
with the top row outlining the experimental manipulations and the bottom row showing 
the dependent measures. (B) The sagittal diagram modified from the mouse brain atlas 
(Paxinos and Franklin, 2007) shows placement of one microdialysis probe in the 
prefrontal cortex (PFC) and a second microdialysis probe in the pontine reticular 
formation (PRF).  The dialysis probe membranes are drawn to scale (1 mm length, 0.24 
mm diameter).  The distance between the two probe tips is 8.56 mm.  The laterodorsal 
tegmental (LDT) and pedunculopontine tegmental (PPT) nuclei provide cholinergic input 
to the PRF. 
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A CMA/110 liquid switch was used to dialyze the prefrontal cortex with Ringer’s 
followed by Ringer’s containing drug (Fig. 3.1A) and to dialyze the pontine reticular 
formation with Ringer’s.  Dialysis samples were collected every 12.5 min.  Six samples 
were collected during dialysis with Ringer’s (control) then six samples were collected 
during dialysis with drug.  Each 25 µl dialysis sample was injected into a HPLC/EC 
system (Bioanalytical Systems, (BAS), West Lafeyette, IN).  The sample was carried 
through the system in 50 mM Na2HPO4 mobile phase (pH 8.5) at a flow rate of 1 ml/min.  
ACh and choline were separated by an analytical column and then broken down into 
hydrogen peroxide by an immobilized enzyme reaction column.  The hydrogen peroxide 
was detected by a platinum electrode (0.5 V applied potential) in reference to an 
Ag+/AgCl electrode.   Chromgraph software (Bioanalytical Systems Inc.) was used to 
digitize and quantify the resulting chromatograms compared to a series of ACh standards.  
The percentage of a known ACh solution recovered by the probe was determined before 
and after every experiment.  If the pre-and post-experiment probe recoveries were 
significantly different by t-test, the data from that experiment were discarded. 
Data Analysis.  ACh release was expressed as percent of ACh measured during 
dialysis with Ringer’s (control condition).  Drug effects on pontine reticular formation 
ACh release were analyzed using Students t-test (GBStatTM v6.5.6, Dynamic 
Microsystems, Inc., Silver Spring, MD).  Data are reported as mean ± standard error of 
the mean (SEM).  A probability value of P ≤ 0.05 was considered to be statistically 
significant.  Seven days after the experiment mice were deeply anesthetized and 
decapitated.  The brains were removed, frozen, and coronally sectioned (40 µm thick).  
The sections were fixed with hot (80°C) paraformaldehyde vapor and stained with cresyl 
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violet.  The location of a glial scar caused by the microdialysis probe was determined by 
comparing stained sections with a mouse brain atlas (Paxinos and Franklin, 2001).  
Results were included in the group data only for experiments in which histology 
confirmed that the microdialysis probes had been placed within the prefrontal cortex and 
the pontine reticular formation. 
 
RESULTS 
Time course of ACh release in the pontine reticular formation 
Pontine reticular formation ACh release (Fig. 3.2A) was collected during dialysis 
with Ringer’s in both the pontine reticular formation and the prefrontal cortex (75 min; 
control) followed by continuous dialysis with Ringer’s in the pontine reticular formation 
and dialysis with Ringer’s plus drug to the prefrontal cortex (75 min).  The ACh release 
from the pontine reticular formation dialysis samples was averaged across each condition 
(Ringer’s or prefrontal cortex drug) (Fig. 3.2B).  Dialysis delivery of the adenosine A2A 
receptor agonist CGS to the prefrontal cortex significantly increased pontine reticular 
formation ACh release (t = 5.9; df = 10; p < 0.0001).   
 
 




Figure 3.2.  ACh release in the pontine reticular formation (PRF) during a single 
representative experiment.  (A) illustrates an experiment time course.  Bars show 6 
sequential PRF ACh samples collected during dialysis with Ringer’s (control, hatched 
bars) followed by 6 samples collected during dialysis of the prefrontal cortex with 
Ringer’s plus CGS (solid bars).  Each bar represents 1 ACh sample from the same mouse.  
(B) Dialysis delivery of CGS to the prefrontal cortex caused a significant increase in 
pontine reticular formation ACh release (49.9%).   
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Dialysis delivery of adenosine A1 and A2A receptor agonists and antagonists to the 
prefrontal cortex altered pontine reticular formation ACh release 
Analysis of the group data shows that CGS, an adenosine A2A receptor agonist, 
delivered to the prefrontal cortex increased pontine reticular formation ACh release (Fig. 
3.3A) (t = 9.8; df = 4; p < 0.001).  Microdialysis delivery of the adenosine A1 receptor 
agonist SPA to the prefrontal cortex decreased pontine reticular formation ACh release 
(Fig. 3.3B) (t = 8.1; df = 4; p < 0.001).  Dialysis delivery of caffeine (Fig. 3.3C) (t = 21.4; 
df = 4; p < 0.0001) or the adenosine A1 receptor antagonist DPCPX (Fig. 3.3D) (t = 16.0; 
df = 4; p < 0.0001) to the prefrontal cortex increased pontine reticular formation ACh 
release.  Figure 3.4 illustrates the locations of the dialysis probes (A and B) and 
representative cresyl violet stained histological sections (C and D) showing the glial scar 
produced by the dialysis probe. 
 




Figure 3.3.  Adenosine A1 and A2A receptor agonists and antagonists delivered to the 
prefrontal cortex (PFC) significantly alter ACh release in the pontine reticular formation 
(PRF).  (A) Dialysis administration of the adenosine A2A receptor agonist CGS to the 
prefrontal cortex caused a significant increase in pontine reticular formation ACh release, 
whereas (B) prefrontal cortex SPA, an adenosine A1 receptor agonist, caused a significant 
decrease in pontine reticular formation ACh release.  Pontine reticular formation ACh 
release was also increased by prefrontal cortex (C) caffeine and the (D) adenosine A1 
receptor antagonist DPCPX.  Each drug was tested in 3 mice. 





Figure 3.4.  The locations of (A) 12 prefrontal cortex and (B) 12 pontine reticular 
formation microdialysis sites are illustrated on coronal diagrams from a mouse brain atlas 
(Paxinos and Franklin, 2007).  Dialysis probe membranes are represented by cylinders 
and are drawn to scale (1 mm length, 0.24 mm diameter).  Average stereotaxic 
coordinates (mean ± SEM) for the prefrontal cortex probe sites were 2.89 ± 0.08 mm 
anterior to bregma and 1.75 ± 0.05 mm lateral to the midline and for the pontine reticular 
formation were 4.72 ± 0.15 mm posterior to bregma and 0.7 ± 0.12 mm lateral to the 
midline.  The cresyl violet-stained coronal sections (C and D) show typical prefrontal 
cortex and pontine reticular formation microdialysis sites (arrow).  In relation to bregma, 
the prefrontal cortex section is approximately 2.96 mm anterior and the pontine reticular 
formation section is approximately 4.72 mm posterior. 
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DISCUSSION 
The present data show that adenosine A1 and A2A receptor agonists and 
antagonists delivered by microdialysis to the prefrontal cortex alter pontine reticular 
formation ACh release.  This is the first study to demonstrate that pharmacological 
manipulation of prefrontal cortex adenosine A1 and A2A receptors alters cholinergic 
neurotransmission in the pontine reticular formation.  The results are discussed relative to 
related studies and the role of the prefrontal cortex in regulating behavioral arousal. 
 
Prefrontal cortex adenosine A1 and A2A receptors modulate behavioral arousal by 
altering pontine reticular formation ACh release. 
Dialysis delivery of the adenosine A2A receptor agonist CGS to the prefrontal 
cortex increased pontine reticular formation ACh release (Fig. 3.3A).  This finding is 
consistent with an increase in ACh release caused by local administration of CGS to the 
pontine reticular formation in B6 mouse (Coleman et al., 2006).  Prefrontal cortex SPA, 
an adenosine A1 receptor agonist, decreased pontine reticular formation ACh release (Fig. 
3.3B) similar to a study in cat where local administration of SPA to homologous regions 
of the pontine reticular formation also decreased ACh release and significantly delayed 
resumption of wakefulness following anesthesia (Tanase et al., 2003).  The Fig. 3 data are 
consistent with the interpretation that prefrontal cortex adenosine A1 and A2A receptors in 
B6 mouse modulate behavioral arousal, in part, via a descending pathway that modulates 
ACh levels in a pontine component of the ascending reticular activating system.  
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Endogenous adenosine within the prefrontal cortex modulates behavioral arousal by 
varying ACh release within the pontine reticular formation. 
Dialysis delivery of caffeine (Fig. 3.3C) and the adenosine A1 receptor antagonist 
DPCPX (Fig. 3.3D) caused a significant increase in pontine reticular formation ACh 
release.  These data, taken together with the earlier finding that prefrontal cortex 
adenosine A1 and A2A receptors modulate ACh release, behavioral arousal, and sleep 
(Van Dort CJ et al., 2008) suggest that prefrontal cortex adenosine modulates behavioral 
arousal, in part, by altering pontine reticular formation ACh release.  Cholinergic 
neurotransmission in the pontine reticular formation is important for the regulation of 
behavioral arousal (Lydic and Baghdoyan, 2005, Steriade and McCarley, 2005).  Pontine 
reticular formation ACh levels vary with states of sleep and wakefulness.  Pontine 
reticular formation ACh levels are the highest during REM sleep, followed by 
wakefulness, and the lowest during NREM sleep (Kodama et al., 1990, Leonard and 
Lydic, 1995, Leonard and Lydic, 1997).  Enhancing cholinergic neurotransmission in the 
pontine reticular formation by local delivery of the acetylcholinesterase inhibitor 
neostigmine or the cholinergic agonist carbachol causes a REM sleep-like state in mouse 
(Lydic et al., 2002), rat (Bourgin et al., 1995), and cat (Baghdoyan et al., 1984).  Dialysis 
delivery of carbachol to the pontine reticular formation of mouse significantly decreased 
ACh release in the prefrontal cortex (DeMarco et al., 2004).  The present results extend 
Moruzzi and Magoun’s 1949 concept of an ascending arousal activating system (Moruzzi 
and Magoun, 1949) by providing functional evidence for a descending pathway from the 
prefrontal cortex to the pontine reticular formation.  Given the known role of the 
prefrontal cortex in executive function (Fuster, 2001) the results suggest one pathway for 
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top-down, volitional modulation of arousal.  The ability of the executive cortex to recruit 
input from the ascending cortical activating system may provide one mechanism allowing 
sleep-deprived individuals to cope with attention demanding tasks (Chee et al., 2008). 
 
Limitations and Conclusions 
The finding that the prefrontal cortex alters ACh release in the pontine reticular 
formation does not imply a single mechanism.  The prefrontal cortex projects to many 
caudal brain regions known to regulate behavioral arousal (Gabbott et al., 2005, Morgane 
and Mokler, 2006).  The finding that the prefrontal cortex can alter neurotransmitter 
release in the pontine reticular formation, also fits with the concept of “top-down” 
processing used to describe the ability of the prefrontal cortex to control attention 
(Buschman and Miller, 2007).  Although the role of the prefrontal cortex in the volitional 
control of attention has been demonstrated by many studies (Reviewed in (Miller and 
D'Esposito, 2005, Sarter et al., 2006)), the present results are the first to suggest a top-
down regulatory control system for behavioral arousal.  The present data suggest that the 
ability to consciously decide to stay awake despite homeostatic and circadian drive to 
sleep may be mediated, in part, by prefrontal cortex adenosine A1 and A2A receptors 
modulating pontine reticular formation ACh release. 
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SUMMARY AND CONCLUSION 
 
 
This Ph.D. thesis research used a pharmacological approach to elucidate the 
mechanisms by which prefrontal cortex adenosine receptors modulate the waking 
phenotypes of acetylcholine (ACh) release, anesthesia recovery time, 
electroencephalographic (EEG) delta power, and sleep.  The results summarized in this 
thesis are consistent with the interpretation that adenosine A1 and A2A receptors in the 
prefrontal cortex of B6 mouse modulate cortical ACh release, behavioral and EEG 
arousal (Van Dort CJ et al., 2006a, Van Dort CJ et al., 2006b, Van Dort CJ et al., 2007a), 
and sleep (Van Dort CJ et al., 2007b), in part, by altering pontine reticular formation ACh 
release.  These results are discussed below in relation to possible mechanisms for 
prefrontal cortex modulation of arousal, relevant recent studies, and potential clinical 
relevance.   
A systematic review of the literature shows the present research to be the first to 
characterize adenosinergic and cholinergic interactions in the prefrontal cortex of B6 
mouse.   Functions of the prefrontal cortex, such as working memory (Gabrieli et al., 
1998) and attention (Chee et al., 2008, Drummond et al., 2001, Mander et al., 2008, 
Muzur et al., 2002, Sarter et al., 2006), are negatively affected by sleep deprivation.  This 
thesis focused on the frontal association area of the prefrontal cortex, the mouse homolog 
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of the human and primate prefrontal cortex (Muzur et al., 2002, Uylings and van Eden, 
1990, Uylings et al., 2003).   
The Chapter 2 data support the hypotheses of Aims 1 and 2 and demonstrate that 
prefrontal cortex adenosine A1 and A2A receptors modulate the waking phenotypes of 
ACh release, anesthesia recovery time, EEG delta power, and sleep.  Unilateral dialysis 
delivery of CGS, an adenosine A2A receptor agonist, to the prefrontal cortex of B6 mouse 
increased cortical ACh release (Fig. 2.2).  This increase in ACh release is consistent with 
previous data showing that administration of CGS to the pontine reticular formation of 
B6 mouse increased ACh release (Coleman et al., 2006).  Dialysis delivery of the 
adenosine A1 receptor agonist SPA to the prefrontal cortex significantly decreased 
waking phenotypes including a decrease in prefrontal cortex ACh release and increase in 
anesthesia recovery time (Fig. 2.3).  The present finding that dialysis delivery of SPA to 
the prefrontal cortex delayed resumption of wakefulness from anesthesia is consistent 
with the finding that dialysis administration of SPA to the pontine reticular formation of 
cat decreased ACh release and increased anesthesia recovery time (Tanase et al., 2003).  
The good agreement in results obtained from two different species supports the 
interpretation that adenosine A1 and A2A receptors modulate ACh release and anesthesia 
recovery time.  The effects of both CGS and SPA were concentration dependent and 
blocked by their respective selective antagonist suggesting that the CGS and SPA 
induced changes in ACh release and anesthesia recovery time were receptor mediated.  
The opposing effects of the adenosine A2A versus A1 receptor agonist discovered in the 
present thesis results fit with the known signaling mechanisms of adenosine receptors.  
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Adenosine A2A receptors are excitatory G-protein coupled whereas adenosine A1 
receptors are inhibitory G-protein coupled (Dunwiddie and Masino, 2001).   
The decrease in mouse prefrontal cortex ACh release caused by SPA is consistent 
with findings in rat cerebral cortex where the adenosine A1 receptor agonist N6-
Cyclopentyladenosine (CPA) also decreased basal ACh levels (Phillis et al., 1993).  In 
contrast to the present study, the adenosine A2A receptor agonist CGS did not alter basal 
ACh levels in rat cerebral cortex (Phillis et al., 1993).  Additional data show that 
electrically stimulated ACh release from rat cortical slices was decreased by the 
adenosine A1 receptor agonist CPA, whereas the adenosine A2A receptor agonist CGS, 
did not alter ACh release (Broad and Fredholm, 1996).  In urethane anesthetized rats, no 
adenosine A1 or A2A receptor agonist or antagonist tested altered basal ACh release from 
the barrelfield of the somatosensory cortex (Materi et al., 2000).  Therefore, the Materi et 
al. study examined the effects of adenosine receptor agonists and antagonists on evoked 
cortical ACh release induced by electrical stimulation of the pedunculopontine tegmental 
nucleus (Materi et al., 2000).  Local dialysis delivery of adenosine or the adenosine A1 
receptor agonist CPA to the somatosensory cortex decreased evoked ACh release in the 
somatosensory cortex and this decrease in evoked ACh release was blocked by the 
adenosine A1 receptor antagonist DPCPX (Materi et al., 2000).  Both the Materi et al. 
study and the current thesis data agree that adenosine A1 receptor agonists decrease 
cortical ACh release.  In contrast to the present thesis results, neither the adenosine A2A 
receptor agonist CGS, the adenosine A1 receptor antagonist DPCPX, or the adenosine A1 
and A2A receptor antagonist caffeine delivered to the somatosensory cortex alone, altered 
evoked ACh release (Materi et al., 2000).  The discrepancies between the Materi et al. 
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findings and the present research may have resulted from the fact that the two studies 
used different species, different brain regions, and different anesthetics.  In contrast to the 
present studies of ACh release from the prefrontal cortex of isoflurane anesthetized B6 
mouse, the Materi et al. data were derived from the somatosensory cortex of urethane 
anesthetized Wistar rat.  Urethane has been shown to exert non-specific effects on 
muscarinic and nicotinic cholinergic, as well as γ-aminobutyric acid (GABA)ergic, 
glycinergic, and N-methyl-D-aspartate (NMDA) receptors (Hara and Harris, 2002).  
Having demonstrated that exogenous adenosine A1 and A2A receptor agonists 
delivered to the prefrontal cortex alter waking phenotypes, additional experiments were 
designed to determine whether endogenous adenosine acting at adenosine A1 and/or A2A 
receptors in the prefrontal cortex also modulates ACh release in the pontine reticular 
formation.  The adenosine A1 and A2A receptor antagonist caffeine or the adenosine A1 
receptor antagonist DPCPX were delivered to the prefrontal cortex by microdialysis and 
both significantly increased waking phenotypes (Fig. 2.4 and 2.5).  Similar to the increase 
in prefrontal cortex ACh release caused by local administration of DPCPX in the present 
thesis study, systemic administration of the adenosine A1 receptor antagonist 8-
dicyclopropylmethyl-1,3-dipropylxanthine to rat increased cerebral cortex ACh release 
(Kurokawa et al., 1996).  Interestingly, the present thesis results demonstrated that the 
adenosine A2A receptor antagonist ZM did not alter ACh release, anesthesia recovery 
time, or EEG delta power (Fig. 2.4 and 2.5).  The finding that the A2A receptor antagonist 
did not alter waking phenotypes was novel because a study using adenosine A1 and A2A 
receptor knockout mice demonstrated that caffeine was able to promote wakefulness in 
adenosine A1 but not A2A receptor knockout mice (Huang et al., 2005).  The authors 
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interpreted these data to suggest that caffeine promotes wakefulness through blockade of 
adenosine A2A receptors and not adenosine A1 receptors (Huang et al., 2005).  In contrast 
to the study of adenosine receptor knockout mice, the good agreement between the 
present caffeine and DPCPX data clearly indicate a role for prefrontal cortex adenosine 
A1 receptors in the regulation of behavioral arousal in normal B6 mice.  The differences 
between the Huang et al. study and the thesis data may be due to the type of mouse model 
used, the route of drug administration, or the concentration of caffeine.  An 
acknowledged limitation of knockout mice in which a gene has been ablated is 
compensation by other genes (Crawley, 2000, Robert, 1998).  The Huang et al. study 
administered caffeine systemically by intraperitoneal injection whereas the drugs tested 
in the present thesis research were delivered locally to the prefrontal cortex.  
Alternatively, the concentration of caffeine used in the Huang et al. study has been shown 
to induce locomotor activity (Fredholm et al., 1999, Lindskog et al., 2002).  Therefore, 
the increase in wakefulness may be secondary to the increase in activity.  
There is debate as to which adenosine receptor subtype, A1 or A2A, is more 
important for the role of adenosine in arousal state control.  Interestingly, studies of intact 
rats, cats, and humans, using pharmacology and sleep deprivation, show that adenosine 
A1 receptors mediate the sleep promoting effects of adenosine.  In contrast, studies using 
adenosine receptor knockout mice suggest that adenosine A2A receptors mediate the sleep 
promoting effects of adenosine.  For example, systemic or intracerebroventricular 
administration of the adenosine A1 receptor agonist CPA to rat causes a concentration 
dependent increase in slow wave activity during NREM sleep, mimicking the 
electroencephalographic changes that occur with sleep deprivation (Benington et al., 
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1995).  In cat, microdialysis delivery of the adenosine A1 receptor antagonist 
cyclopentyltheophylline to the cholinergic basal forebrain increases wakefulness and 
decreases NREM and REM sleep and the adenosine A1 receptor agonist 
cyclohexyladenosine decreases wakefulness and increases sleep (Strecker et al., 2000).  
Sleep deprivation in rat causes a significant increase in adenosine A1 receptor mRNA 
(Basheer et al., 2001) and protein (Basheer et al., 2007) in the basal forebrain whereas 
adenosine A2A receptor mRNA decreases (Basheer et al., 2001).  These results suggest 
that basal forebrain adenosine A1 receptors contribute, in part, to the sleep inducing 
action of increased basal forebrain adenosine during prolonged wakefulness.  Adenosine 
A1 receptor binding is also up regulated in the cortex and corpus striatum after REM 
sleep deprivation in rat (Yanik and Radulovacki, 1987).  In humans, sleep deprivation 
causes a global brain increase in adenosine A1 receptor binding demonstrated by positron 
emission tomography, with the highest binding in the orbitofrontal cortex (Elmenhorst et 
al., 2007).  These studies support the interpretation that cortical adenosine A1 receptors 
contribute to sleep homeostasis in humans as well as non-human animals.  The thesis data 
demonstrating that adenosine A1 receptors in the prefrontal cortex mediate, in part, the 
sleep promoting effect of adenosine, fit well with data from intact rat, cat, and human. 
Given the striking effects of adenosine A1 and A2A receptor agonists and 
antagonists on sleep and wakefulness, it was surprising that adenosine A1 and A2A 
receptor knockout mice did not have a more pronounced phenotype.  Both adenosine A1 
(Stenberg et al., 2003) and adenosine A2A (Urade et al., 2003) receptor knockout mice 
survive development with no major defects.  These knockout mice also show normal 
circadian sleep wake cycles compared to wildtype mice (Stenberg et al., 2003, Urade et 
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al., 2003).  In view of pharmacological studies of intact animals showing clear functions 
for adenosine A1 and A2A receptors, it will be interesting to determine if differences can 
be found in sleep and wakefulness if future studies use conditional (where the gene can 
be knocked out after development) and regional (where the gene can be knockout out in 
specific brain regions) gene knockouts.  One difference between the adenosine A1 and 
A2A receptor knockout mice is their response to a pharmacological challenge of caffeine.  
Caffeine promotes wakefulness in adenosine A1 but not A2A receptor knockout mice, 
suggesting that in these genetically altered mice caffeine promotes arousal by blocking 
adenosine A2A and not A1 receptors (Huang et al., 2005).   
Cortical ACh levels vary with the arousal state of the animal (Jasper and Tessier, 
1971, Marrosu et al., 1995) therefore, the foregoing studies used anesthesia to hold state 
constant during the intensive concentration response curve and antagonist blocking data 
collection.  These results encouraged another set of experiments using intact, 
unanesthetized mice to determine whether prefrontal cortex adenosine A1 receptors also 
modulate sleep and wakefulness.  Microinjection of the adenosine A1 receptor antagonist 
DPCPX into the prefrontal cortex increased wakefulness, decreased NREM sleep, and 
did not change REM sleep.  These data are consistent with the interpretation that 
prefrontal cortex adenosine, acting through adenosine A1 receptors, promotes sleep and 
inhibits wakefulness, in addition to inhibiting the waking phenotypes discussed above.  
These results are supported by a recent study demonstrating that DPCPX reversed ethanol 
induced sleep when microinjected into the basal forebrain of rat (Thakkar et al., 2008).  
In cat, microdialysis delivery of a different adenosine A1 receptor antagonist, 
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cyclopentyltheophylline, to the basal forebrain also increased wakefulness and decreased 
sleep (Strecker et al., 2000). 
Early brain transection studies (Jouvet, 1962) revealed that rhythmic oscillations 
between traits characteristic of NREM sleep and REM sleep persist after the forebrain is 
removed.  These studies helped localize the central pattern generator for REM and 
NREM sleep to the pontine brainstem (Jouvet, 1962).  The data reported in Chapter 2 
showed that adenosine A1 and A2A receptors in the prefrontal cortex modulate ACh 
release, behavioral and EEG arousal, and sleep.  In view of early studies demonstrating 
that rostral brain regions are not necessary for generating REM and NREM sleep, the 
Chapter 2 results imply that the prefrontal cortex modulates states of sleep and 
wakefulness by way of descending input to caudal arousal control centers.  Therefore, 
Chapter 3 experiments were designed to determine if pontine reticular formation ACh 
release was one mechanism by which prefrontal cortex adenosine A1 and A2A receptors 
modulate behavioral arousal.  Microdialysis delivery of an adenosine A2A receptor 
agonist, adenosine A1 receptor antagonist, or caffeine to the prefrontal cortex increased 
pontine reticular formation ACh release whereas an adenosine A1 receptor agonist 
decreased pontine reticular formation ACh release.  These findings are the first to 
demonstrate that pharmacological manipulation of the prefrontal cortex can alter 
neurotransmitter release in the pontine reticular formation.  These results also suggest 
that one mechanism through which prefrontal cortex adenosine A1 and A2A receptors 
modulate behavioral arousal is by altering pontine reticular formation ACh release.   
Adenosinergic compounds have been used to manipulate arousal and pain in 
humans.  The most common adenosinergic compound used in humans is the stimulant 
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caffeine (Fredholm et al., 1999).  Adenosine also has antinociceptive properties (Foster et 
al., 1994, Sawynok, 1998, Sawynok and Liu, 2003, Sollevi, 1997) but only a few studies 
have investigated the antinociceptive properties of adenosine in humans (Segerdahl et al., 
1995, Segerdahl et al., 1996).  In subjects undergoing breast (Segerdahl et al., 1995) or 
shoulder surgery (Segerdahl et al., 1996), peroperative systemic adenosine infusion 
decreased postoperative analgesic requirement (Segerdahl et al., 1995) as well as the 
level of isoflurane needed to maintain unconsciousness during surgery (Segerdahl et al., 
1995, Segerdahl et al., 1996). 
Further evidence that adenosinergic neurotransmission is involved in human sleep 
homeostasis stems from studies of polymorphisms in adenosine related genes in humans.  
Adenosine deaminase plays a role in adenosine metabolism by breaking down adenosine 
into inosine.  A polymorphism in the adenosine deaminase gene that decreases the 
breakdown of adenosine, thereby increasing adenosine levels, causes an increase in deep 
slow waves during NREM sleep (Retey et al., 2005).  A different polymorphism in the 
adenosine A2A receptor gene is correlated with anxiety induced by caffeine (Alsene et al., 
2003).  This polymorphism in the adenosine A2A receptor is also associated with 
interindividual differences in sensitivity to caffeine and the ability of caffeine to disrupt 
sleep quality (Retey et al., 2007).  These differential arousal phenotypes associated with 
genetic polymorphisms in adenosine related genes suggests that adenosine plays a role in 
sleep homeostasis in humans. 
In conclusion, four novel findings emerged from this thesis research in B6 mouse: 
1) prefrontal cortex adenosine A1 and A2A receptors modulate cortical ACh release, 
behavioral and EEG arousal, 2) caffeine promotes wakefulness, in part, by blocking 
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prefrontal cortex adenosine A1 receptors, 3) adenosine A1 receptors in the prefrontal 
cortex modulate sleep and wakefulness, and 4) prefrontal cortex adenosine A1 and A2A 
receptors modulate behavioral arousal, in part, by altering pontine reticular formation 
ACh release.  Taken together, these results are consistent with the interpretation that 
adenosine A1 and A2A receptors in the prefrontal cortex of B6 mouse play an important 
role in regulating behavioral arousal and sleep.   
The present thesis results encourage further studies to elucidate the mechanism of 
caffeine action on wakefulness as well as prefrontal cortex control of behavioral arousal.  
From Aims 1 and 2, a number of potential future studies arise, including addition of 
concentration response curve data for the effects of DPCPX microinjected into the 
prefrontal cortex on sleep and wakefulness or microinjecting other adenosine receptor 
agonists and antagonists like CGS, SPA, and caffeine into the prefrontal cortex and 
recording their effects on sleep and wakefulness.  Concentration response and antagonist 
blocking data from these sleep studies would help characterize the role of adenosine A1 
and A2A receptors in the prefrontal cortex on sleep and wakefulness.  Another approach to 
determining the wakefulness promoting mechanism of caffeine is to combination 
systemic and local drug delivery.  Systemic administration of caffeine increases 
wakefulness (Huang et al., 2005).  If this increase in wakefulness by caffeine can be 
blocked by local administration of the adenosine A1 receptor agonist to the prefrontal 
cortex, this would suggest that one mechanism by which caffeine promotes wakefulness 
is by blockade of adenosine A1 receptors in the prefrontal cortex.  Aim 3 results support 
further investigation of the role of the prefrontal cortex on behavioral arousal.  One way 
to determine what brain regions are activated and deactivated by pharmacological 
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manipulation of the prefrontal cortex would be by imaging studies.  New rodent magnetic 
resonance imaging technology makes it possible to measure regional brain activity in the 
live animal.  Another way to look at where the prefrontal cortex is changing activity 
would be by injecting an adenosine receptor agonist or antagonist into the prefrontal 
cortex, slicing the brain, and staining for immediate early gene c-fos expression, a marker 
of neuronal activity.  Brain regions that might show changes in activity after prefrontal 
cortex stimulation would be the cholinergic basal forebrain or the lateraldorsal tegmental/ 
pedunculopontine tegmental nuclei.  Once candidate brain regions are identified, dual 
dialysis experiments could be performed to determine the neurochemical phenotype of 
the region involved.  Another useful tool for studying adenosine receptor signaling is 
knockout mice.  As discussed earlier, adenosine A1 and A2A receptor knockout mice have 
been made and could be used for further pharmacological analysis of the receptor 
systems involved in the regulation of behavioral arousal, sleep, and wakefulness. 
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NEUROCHEMICAL MODULATORS OF SLEEP AND ANESTHETIC STATES 
 
The regulation of consciousness is a fundamental question that has a long and 
storied association with philosophy.  Today, consciousness studies command a central 
position in contemporary neuroscience (Blackmore, 2004, Gallagher, 2000, Koch, 2004).  
The complexities of consciousness studies and the pressing demands of clinical care have 
led most anesthesiologists to focus on research problems with pragmatic outcomes.  Yet 
the ability to accurately assess and manipulate states of consciousness with anesthetic 
drugs is the ultimate concern for every surgical patient and anesthesia provider.  This 
volume recognizes consciousness studies as a legitimate and accessible concern for 
anesthesiology.  This chapter considers the relationship between molecules known to 
regulate the loss of consciousness during anesthesia and molecules that regulate the loss 
of consciousness during physiological sleep.  Sleep neurobiology has been shown to 
provide unique insights into the study of consciousness (Hobson et al., 1999, Hobson et 
al., 2000, Hobson and Pace-Schott, 2002).  The proposal (Lydic, 1996, Lydic and 
Baghdoyan, 1998) that neuronal networks that evolved to generate states of sleep and 
wakefulness also contribute to the generation of anesthetic states has been supported by 
many laboratories (Fiset, 2003, Franks, 2008, Hudetz et al., 2003, Kelz et al., 2008, Lydic 
and Baghdoyan, 2005a, Meuret et al., 2000, Nelson et al., 2002b, Nelson et al., 2003, 
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Pain et al., 2000, Tung et al., 2005, Yasuda et al., 2003).  There is evidence that the loss 
of consciousness during sleep is caused, in part, by the loss of functional connectivity and 
information processing (Massimini et al., 2005).  Functional connectivity is critically 
dependent on neurochemical transmission.  Therefore, this chapter focuses on 
intravenous and volatile anesthetics that have been shown to alter endogenous 
neurotransmitters known to regulate states of consciousness.  Reviews on sleep from an 
anesthesiology perspective are available elsewhere (Lydic and Baghdoyan, 1998, Lydic 
and Baghdoyan, 2005b, Lydic and Baghdoyan, 2005c, Lydic and Baghdoyan, 2007, Tung 
and Mendelson, 2004). 
The present overview is derived from a September 2007 PubMed title search of 
peer-reviewed papers linking 10 commonly used anesthetics with 11 endogenous 
molecules known to regulate states of consciousness.  The list of intravenous anesthetics 
includes propofol, pentobarbital, ketamine, etomidate, and midazolam.  The list of 
volatile anesthetics includes isoflurane, sevoflurane, nitrous oxide, xenon, and desflurane.  
The 11 endogenous molecules known to regulate sleep/wake states (Steriade and 
McCarley, 2005) include acetylcholine (ACh), γ-aminobutyric acid (GABA), glutamate, 
adenosine, dopamine, histamine, serotonin, norepinephrine, hypocretin/orexin, glycine, 
and galanin.  This 10 by 11 matrix was searched from 1950 to 2007 and identified 660 
references.  A search of the last 10 years (1997 to 2007) revealed a total of 192 references 
(Tables 1 and 2).  
 
   
 90 
I.  INTRAVENOUS ANESTHETICS ALTER NEUROTRANSMITTERS THAT 
REGULATE SLEEP AND WAKEFULNESS.  The endogenous neurotransmitters and 
neuromodulators ACh, GABA, glutamate, the monoamines (dopamine, histamine, 
serotonin, and norepinephrine), and adenosine contribute to generating and maintaining 
states of sleep and wakefulness.  The following section selectively highlights studies 
investigating the effects of the most cited agents (Table 1), propofol and ketamine, on 
these neurotransmitter systems. 
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Table A.1. Intravenous Anesthetic Agents and Sleep-Related Neurotransmitters. 
The matrix summarizes the total number of peer reviewed publications obtained from a 
PubMed search spanning from 1997 to 2007, in which the title listed both the intravenous 
(I.V.) agent (rows) and the endogenous neurotransmitter molecule (columns).  The first 
column lists the five I.V. agents and columns 2 through 6 list the neurotransmitters 
studied.  Monoamines include serotonin, norepinephrine, dopamine, and histamine.  






Anesthetics Monoamines GABA Glutamate Acetylcholine Adenosine Total 
Propofol 12 7 6 4 6 35 
Ketamine 13 4 5 11 1 34 
Pentobarbital 4 8 2 1 2 17 
Midazolam 2 4 4 1 2 13 
Etomidate 1 6 1 1 0 9 
Total 32 29 18 18 11 108 
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1.  Propofol 
Propofol was successfully introduced into clinical practice during the late 1980s.  
Propofol is a small hydrophobic alkylphenol derivative and its anesthetic actions are 
mediated primarily via the GABAA receptor (Reves et al., 2005).  Propofol also alters the 
actions of other sleep-related neuromodulators.  As reviewed below, the anesthetic effects 
of propofol also may be mediated by its effects on monoaminergic, GABAergic, 
glutamatergic, cholinergic, and adenosinergic neurotransmission in brain regions known 
to regulate sleep and wakefulness.   
1.1  Monoamines:  A consistent finding from studies of sleep neurobiology is that 
monoamines promote wakefulness (reviewed in Ref. (Steriade and McCarley, 2005)).  
Serotonin containing neurons in the dorsal raphe, norepinephrine containing neurons in 
the locus coeruleus, and histaminergic neurons in the tuberomammillary nucleus 
discharge at their fastest rates during wakefulness, slow their discharge rates during non-
rapid eye movement (NREM) sleep, and are silent during rapid eye movement (REM) 
sleep.  This wake-on/sleep-off discharge pattern is consistent with a role for these 
monoaminergic neurotransmitters in promoting wakefulness.  Interestingly, although 
dopaminergic neurons in the ventral tegmental area do not change their discharge rates 
across the sleep-wake cycle, a large body of evidence demonstrates that dopamine also 
promotes wakefulness (reviewed in Ref. (Lydic and Baghdoyan, 2005a)).  
The cell groups described above provide monoaminergic input to the prefrontal 
cortex, which contributes to the regulation of behavioral arousal (Muzur et al., 2002).  
Serotonin levels in rat frontal cortex decrease during sleep compared to wakefulness 
(Bjorvatn et al., 2002), as would be predicted by the wake-on/sleep-off discharge pattern 
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of serotonergic neurons.  Similarly, norepinephrine levels decrease during REM sleep 
compared to wakefulness in rat medial prefrontal cortex (Lena et al., 2005).  Dopamine 
levels in rat medial prefrontal cortex also vary across the sleep wake cycle such that 
dopamine levels are greater during the electroencephalographically (EEG) activated 
states of wakefulness and REM sleep compared to the EEG deactivated state of NREM 
sleep (Lena et al., 2005).  In the locus coeruleus and amygdale, the release of 
norepinephrine and serotonin decreases with sleep whereas dopamine release does not 
change, demonstrating that neurochemical changes during sleep are neurotransmitter and 
brain region dependent (Shouse et al., 2000).   
The elimination of waking consciousness by propofol may be due, in part, to 
suppression of monoaminergic transmission in multiple arousal promoting brain regions.  
Dopamine levels in the nucleus accumbens are greater during wakefulness and REM 
sleep (Lena et al., 2005) than during NREM sleep, and propofol decreases dopamine 
release in the nucleus accumbens (Pain et al., 2002, Schulte et al., 2000).  However, 
propofol increases dopamine and serotonin metabolites in rat somatosensory cortex (Shyr 
et al., 1997).  This finding suggests that propofol increases the release of these 
transmitters in rat somatosensory cortex.  Dopamine and serotonin each can cause 
excitation or inhibition, depending upon the type of receptor they activate.  Thus, it will 
be important to combine electrophysiological and neurochemical studies to provide a 
complete understanding of the effects of anesthetics on monoaminergic 
neurotransmission in specific brain regions. 
Systemic administration of epinephrine, norepinephrine, and dopamine decreases 
arterial blood propofol concentrations and increase cardiac output in sheep under 
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continuous propofol infusion, suggesting that monoamines can reverse propofol 
anesthesia by altering circulation (Myburgh et al., 2001).  Systemic administration of the 
α2 receptor agonist clonidine to rats increases the duration of anesthesia produced by 
propofol and decreases prefrontal cortex norepinephrine release (Kushikata et al., 2002).  
This same study also found that systemic administration of the α2 receptor antagonist 
yohimbine decreases the duration of propofol anesthesia and increases cortical 
norepinephrine release.  Given the important role of monoamines in promoting 
wakefulness, a productive area for future studies will be to determine whether propofol 
inhibits monoaminergic neurotransmission in the prefrontal cortex and the locus 
coeruleus.  The mechanisms of anesthetic action, similar to the neurobiology of sleep, 
will be better understood as the effects of anesthetics on neurotransmission are elucidated 
on a brain region-by-region basis. 
1.2  GABA:  GABA is an inhibitory amino acid involved in actively generating 
sleep (Steriade and McCarley, 2005) and anesthesia (Orser, 2006).  The GABAA receptor 
is made up of 5 subunits.  The α, β, and γ subunits all have been shown to be involved in 
the regulation of sleep and anesthesia.  Most GABAA receptors are composed of 2α, 2β, 
and 1γ subunit (Bormann, 2000).  The combination of receptor subtypes that comprise 
the GABAA receptor varies in different brain regions and may account for differential 
effects of drugs in each region (reviewed in Ref. (Mody and Pearce, 2004)).  For 
example, the ability of propofol to activate GABAA receptors varies with the type of α 
subunit (α1 versus α6) (Krasowski et al., 1997).  The endogenous molecule GABA and 
the anesthetic propofol act at different subtypes of the GABAA receptor β2 subunit 
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(molecular weight 54 versus 56 kDa) to produce differential effects on naturally 
occurring sleep versus anesthesia (Bjornstrom and Eintrei, 2003).   
Administration of GABAA receptor agonists or antagonists to brain regions 
regulating states of consciousness can either increase or decrease wakefulness, depending 
on the brain region into which the drugs are administered.  For example, enhancing 
GABAergic inhibition in brain regions that promote arousal, such as the posterior 
hypothalamus, locus coeruleus, and dorsal raphe nucleus, produces sleep (reviewed in 
Ref. (Lydic and Baghdoyan, 2005a)).  In contrast, administering GABAmimetics into the 
pontine reticular formation increases wakefulness and decreases sleep (Sanford et al., 
2003, Watson et al., 2008, Xi et al., 1999).  Anesthetics enhance GABAergic 
neurotransmission by increasing chloride ion conductance and causing neuronal 
hyperpolarization (reviewed in Ref. (Mody and Pearce, 2004)).  In the brain stem locus 
coeruleus and dorsal raphe nucleus, GABA levels are highest during REM sleep (Nitz 
and Siegel, 1997a) and, as noted above, electrophysiological data show that locus 
coeruleus and dorsal raphe neurons cease firing during REM sleep (reviewed in Ref. 
(Steriade and McCarley, 2005)).  Propofol acting at GABAA receptors inhibits the firing 
of locus coeruleus neurons (Chen et al., 1999).  The time to propofol-induced loss of 
righting, used as a measure of sedation, is reduced by microinjecting a GABAA receptor 
antagonist into the tuberomammillary nucleus of the hypothalamus, a wakefulness 
promoting brain region (Nelson et al., 2002b).  This finding suggests that propofol causes 
its sedative effects, in part, by potentiating GABAergic inhibition of hypothalamic 
neurons that promote wakefulness.  Similarly, intravenous administration of gabazine and 
picrotoxin, which block transmission at GABAA receptors, causes large increases in the 
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ED50 for propofol induced immobility in rat (Sonner et al., 2003).  These findings support 
the interpretation that immobility caused by propofol is mediated by GABAA receptors. 
Propofol decreases regional cerebral glucose metabolism in rat (Dam et al., 1990) 
and human (Alkire et al., 1995), and the extent of this depression varies by brain region.  
In humans, regional cerebral glucose metabolism in the cortex showed greater depression 
than in subcortical areas and the greatest depression within the cortex occurred in the left 
anterior cingulate and inferior colliculus (Alkire et al., 1995).  Propofol enhances 
GABAergic neurotransmission (Peduto et al., 1991) and the glucose metabolism data 
correlate with the high benzodiazepine receptor density in human cerebral cortex 
(Braestrup et al., 1977).  The brain regions in which propofol selectively alters cerebral 
metabolism provide targets for further localization of function studies aiming to identify 
the mechanisms by which propofol produces anesthesia. 
1.3  Glutamate: There is considerable evidence that excitatory amino acids 
contribute to the regulation of both sleep- and anesthesia-induced losses of waking 
consciousness.  Glutamatergic transmission in many brain regions is important for sleep 
and anesthesia.  In the brainstem, the laterodorsal tegmental (LDT) and pedunculopontine 
tegmental (PPT) nuclei contain neurons that contribute to REM sleep generation 
(reviewed in Ref. (Lydic and Baghdoyan, 2005a)).  Microinjection of glutamate into the 
PPT induces waking and/or REM sleep depending on the concentration of injected 
glutamate (Datta et al., 2001).  Glutamate levels in the PPT are greater during 
wakefulness than during NREM sleep or REM sleep (Kodama and Honda, 1999), 
consistent with the interpretation that glutamate in the LDT and PPT promotes arousal.  
Further evidence that glutamate promotes wakefulness is shown by systemic 
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administration of the glutamate receptor antagonist riluzole which increases NREM sleep 
and REM sleep in rats (Stutzmann et al., 1988).  However, intracerebroventricular 
administration of the glutamate N-methyl-D-aspartate (NMDA) receptor antagonists 
MK-801 and AP5 decreases REM sleep but does not change NREM sleep or wakefulness 
(Prospero-Garcia et al., 1994).  The present search of the literature identified no studies 
that quantified the effect of propofol on brainstem levels of glutamate. 
Available data demonstrate that the role of glutamate in the regulation of 
consciousness also varies as a function of brain region.  In one study, glutamate levels in 
the orbitofrontal cortex of rat were highest during REM sleep, decreased during 
wakefulness, and lowest during NREM sleep (Lopez-Rodriguez et al., 2007).  These data 
are consistent with the interpretation that glutamate promotes an activated cortical EEG.  
Glutamate levels did not change in the prefrontal cortex during NREM sleep and REM 
sleep compared to levels during wakefulness (Lena et al., 2005), suggesting that cortical 
glutamate is not involved in sleep regulation.  REM sleep deprivation in the rat increased 
cortical glutamate levels (Bettendorff et al., 1996) alternatively implying that glutamate 
in the cortex is somehow involved in the regulation of sleep.  In the basal forebrain, 
microinjection of the glutamate receptor agonists NMDA or α-amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid (AMPA) increased wakefulness and γ (30-60 Hz) EEG 
activity and decreased delta (1-4 Hz) EEG activity (Cape and Jones, 2000).  
Microinjection of NMDA and AMPA into the cholinergic cell area of the basal forebrain 
also caused C-fos activation, a widely used marker of neuronal activity (Cape and Jones, 
2000).  These results are consistent with the interpretation that glutamate in the basal 
forebrain promotes waking consciousness. 
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Data from many species and brain regions demonstrate that propofol decreases 
presynaptic, sodium channel-dependent, glutamate release in cortical, striatal, and 
hippocampal synaptosomes isolated from rats, mice, and guinea pigs (Lingamaneni et al., 
2001, Ratnakumari and Hemmings, 1997).  Only one study showed that propofol did not 
change presynaptic glutamate uptake, binding, or transport in rat cortical isolated nerve 
terminal preparations (Westphalen and Hemmings, 2003b).  Another study by the same 
group demonstrated that propofol did inhibit calcium dependent evoked glutamate release 
in rat cortical synaptosomes (Westphalen and Hemmings, 2003a).  Considered together, 
these data suggest that propofol depresses glutamate neurotransmission but the exact 
mechanism has yet to be elucidated.  
Both NMDA and AMPA receptors are important for the regulation of sleep, but 
only NMDA receptors contribute to the inhibition of currents in cultured mouse 
hippocampal neurons by propofol (Orser et al., 1995).  This inhibition occurs by 
allosteric modulation of the channel versus blockade of the channel.  The literature search 
did not reveal any studies that have characterized the effect of propofol on metabotropic 
glutamate receptors.  An exciting opportunity for future studies is to elucidate the role of 
glutamate in the neurochemical regulation of consciousness.  
1.4  ACh:  There is a long-standing appreciation that cholinergic 
neurotransmission contributes to the loss of consciousness associated with sleep and 
anesthesia (Lydic and Baghdoyan, 1998), (Backman et al., 2004).  Pontine ACh 
contributes to the generation of REM sleep and ACh release within the pontine reticular 
formation is greater during REM sleep than during NREM sleep and wakefulness 
(Leonard and Lydic, 1997).  The clinical finding that the acetylcholinesterase inhibitor 
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physostigmine reverses propofol sedation suggests that propofol produces 
unconsciousness, in part, by disrupting cholinergic neurotransmission (Meuret et al., 
2000).  REM sleep, like wakefulness, is a brain activated state that is characterized by 
increases in cholinergic neurotransmission.  Brain activated states of consciousness, such 
as wakefulness and REM sleep, are promoted by drugs that enhance cholinergic 
neurotransmission.  Thus, the finding that physostigmine causes arousal from propofol 
sedation in humans (Meuret et al., 2000) is consistent with data showing that 
administering neostigmine or carbachol into the pontine reticular formation causes a 
REM sleep-like state in mouse (Lydic et al., 2002), rat (Bourgin et al., 1995), and cat 
(Baghdoyan et al., 1984). 
The foregoing gain-of-function data illustrated by manipulations that increase 
ACh are complimented by loss-of-function studies that chemically eliminate cholinergic 
neurons.  For example, the immunotoxin 192 IgG-Saporin selectively destroys basal 
forebrain cholinergic neurons.  In rat, intracerebroventricular administration of 192 IgG-
Saporin caused a reduction in ACh levels in frontoparietal cortex and hippocampus and a 
decrease in propofol-induced locomotor inhibition (Pain et al., 2000).  These findings 
suggest that inhibition of basal forebrain cholinergic neurons contributes to the hypnotic 
effect of propofol (Pain et al., 2000).  Results from this study are also consistent with the 
notion that anesthetics act in a brain site specific manner, because acetylcholine levels in 
the striatum and cerebellum were not reduced by treatment with 192 IgG-Saporin.  The 
cerebellum and striatum are not brain regions with primary arousal state regulating 
functions.  
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Both muscarinic and nicotinic ACh receptors are important for the regulation of 
sleep and wakefulness.  In vitro studies show that propofol blocks ACh-induced 
muscarinic M1 receptor currents (Nagase et al., 1999).  Propofol also inhibits nicotinic 
ACh receptor mediated currents when the nicotinic receptor is composed of the α4 β2 
subunit but not the α7 homomeric subunit (Flood et al., 1997, Furuya et al., 1999).  ACh 
release within the cerebral cortex and dorsal hippocampus is greater during wakefulness 
and REM sleep than during NREM sleep (Marrosu et al., 1995).  Propofol decreased 
ACh release in rat frontal cortex and hippocampus (Kikuchi et al., 1998), providing 
additional support for the conclusion that propofol causes sedation, in part, by inhibiting 
cholinergic neurotransmission in brain regions that regulate arousal.  
1.5  Adenosine: Consistent with the idea that the neuronal circuits controlling 
sleep are preferentially modulated by anesthetics (Lydic, 1996), local administration of 
propofol to the medial preoptic area, a region known to promote sleep (Steriade and 
McCarley, 2005), decreased latency to sleep onset, increased NREM sleep, and increased 
total sleep time (Tung et al., 2001).  The idea that neuronal networks that generate sleep 
also regulate anesthesia suggests the possibility that prior sleep history may affect 
anesthetic action.  However, no clinical studies have demonstrated any difference in 
anesthetic requirement that is dependent on sleep deprivation.  Preclinical studies have 
shown that sleep deprivation can enhance the sedative effects of propofol.  Rats were 
sleep deprived for 24 h and then administered propofol anesthesia.  Although loss of 
righting response is not identical to sleep, sleep deprivation decreased the latency for and 
prolonged the duration of loss of righting response caused by propofol (Tung et al., 
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2002).  These results also support the view that propofol acts at circuits involved in sleep 
regulation.   
Adenosine is a sleep promoting neuromodulator that acts through 4 G protein 
coupled receptor subtypes, A1, A2A, A2B, and A3.  During prolonged wakefulness brain 
adenosine levels increase within the basal forebrain and cortex (Basheer et al., 2004).  
The ability of sleep deprivation to decrease loss of righting response in rat was partially 
reversed by administration of adenosine A1 and A2A receptor antagonists (Tung et al., 
2005).  Adenosine is known to inhibit excitatory neurotransmission through adenosine A1 
receptors (Tohdoh et al., 2000).  In another study, rats were sleep deprived for 24 h and 
then allowed to have 6 h of ad libitum sleep or 6 h of propofol anesthesia.  Rats that 
experienced ad libitum sleep and propofol anesthesia had similar amounts of NREM 
sleep and REM sleep (Tung et al., 2004).  The authors interpreted these results to suggest 
that propofol anesthesia provides some of the restorative processes that take place during 
naturally occurring sleep.  
 
2.  Ketamine 
Ketamine was first tested clinically in the mid 1960s (Corssen and Domino, 1966, 
Domino et al., 1965).  The term dissociative anesthetic was introduced at that time, and 
referred to the findings that during treatment with ketamine, sensory information 
appeared to reach the sensory cortex but was not accurately perceived due to depression 
of cortical association areas (Corssen and Domino, 1966).  Thus, ketamine caused a 
dissociation between nociceptive input and the subjective experience of nociception.  
Ketamine is a phencyclidine derivative that produces analgesia and amnesia without 
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causing a complete loss of consciousness (Lydic and Baghdoyan, 2002, Reves et al., 
2005, White et al., 1982).  The primary mechanism of ketamine anesthesia is by 
antagonism of NMDA receptors (Kohrs and Durieux, 1998).  Through NMDA receptor 
blockade, ketamine alters the actions of several arousal state related neurotransmitters, as 
outlined below. 
2.1  Monoamines:  Emergence from ketamine anesthesia is often characterized by 
confusion, agitation, visual hallucinations, and delirium (Kohrs and Durieux, 1998).  This 
psychomimetic response has been well-investigated in the context of schizophrenia 
research (Aalto et al., 2005, Kegeles et al., 2000, Moghaddam et al., 1997, Smith et al., 
1998).  Psychotic-like symptoms occurring during ketamine emergence may result from 
ketamine induced increases in dopamine release, particularly in the cerebral cortex.  
Subanesthetic doses of ketamine increase the release of dopamine and serotonin in rat 
prefrontal cortex (Lindefors et al., 1997, Lorrain et al., 2003) and increase dopamine 
release in rat nucleus accumbens (Masuzawa et al., 2003).  Increased dopamine release in 
the nucleus accumbens may contribute to the addictive properties of ketamine 
(Masuzawa et al., 2003).  Brain imaging of healthy human volunteers showed that 
subanesthetic doses of ketamine decreased the binding of a dopamine D2/D3 receptor 
agonist in the posterior cingulate and retrosplenial cortices (Aalto et al., 2005).  This 
decrease in agonist binding was most likely due to a ketamine induced increase in 
dopamine release, as ketamine increases cortical dopamine release in rat (Aalto et al., 
2005, Moghaddam et al., 1997). 
Dopamine receptor subtypes contribute to emergence responses to ketamine.  
Subanesthetic doses of ketamine in rodents cause hyperlocomotor activity characterized 
   
 103 
by staggering and stereotypic head-wagging.  These behavioral responses to ketamine are 
reduced in dopamine D1A receptor knockout mice, suggesting a role for the dopamine 
D1 receptor in mediating emergence responses to ketamine (Miyamoto et al., 2001).  
Studies using in vitro expression systems for dopamine D2 receptors or rat membrane 
preparations have found conflicting results.  One study showed that ketamine has high 
affinity for dopamine D2 receptors (Kapur and Seeman, 2001), whereas another study 
found that ketamine does not cause functional responses via the dopamine D2 receptor 
(Jordan et al., 2006).  In vivo binding studies in humans using PET imaging have 
suggested that subanesthetic doses of ketamine increase dopamine D2 receptor binding in 
the striatum but not the cerebellum (Smith et al., 1998), whereas similar studies using a 
different ligand in monkeys showed no ketamine induced change in D2 receptor binding 
in the basal ganglia or cerebellum (Nader et al., 1999).  As noted repeatedly throughout 
this chapter, the brain region where anesthetic induced changes in neurotransmission 
occur is key to determining the response and the relevance to anesthetic mechanisms of 
action.  Changes in dopamine levels in the cerebral cortex are much more likely to alter 
mental state than are changes in dopamine levels within the striatum or cerebellum. 
Studies using in vitro expression systems of monoamine transmitters indicated 
that ketamine causes a direct inhibition of monoamine transporters, which would enhance 
monoaminergic effects and provide an additional mechanism underlying the ketamine 
emergence reaction (Nishimura and Sato, 1999).  Dopamine transporters, but not 
norepinephrine or serotonin transporters, are selectively inhibited by the S(+)-isomer of 
ketamine (Nishimura and Sato, 1999).  In vivo studies have shown that ketamine 
increases norepinephrine release in rat medial prefrontal cortex (Kubota et al., 1999).  
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Norepinephrine release is normally greater during wakefulness than during physiological 
sleep, thus the ketamine-induced increase in norepinephrine may account for some of the 
dissociative properties of ketamine. 
2.2  GABA:  Ketamine has been shown to have some effects on GABAergic 
neurotransmission, but as of yet it is unclear if ketamine-induced alterations in 
GABAergic transmission are related to the mechanism of ketamine anesthesia.  In vivo 
studies report that systemic administration of the GABAA receptor agonist muscimol 
potentiates ketamine-induced loss of righting response, and coadministration of the 
GABAA receptor antagonist bicuculline with ketamine antagonizes ketamine-induced 
loss of righting (Irifune et al., 2000).  Data from other studies suggest that these responses 
are mediated indirectly.  For example, studies using in vitro expression systems have 
shown that at clinically relevant concentrations, ketamine does not modulate recombinant 
GABAA receptor activity (Flood and Krasowski, 2000).  Furthermore, the GABAA 
receptor antagonists picrotoxin and gabazine cause only a small increase in the ED50 for 
ketamine induced inhibition of mobility in response to a noxious stimulus, suggesting an 
indirect role of GABAA receptors (Sonner et al., 2003).  Finally, acute and chronic 
systemic administration of ketamine does not change GABA levels in rat medial 
prefrontal cortex (Lindefors et al., 1997). 
2.3  Glutamate:  Ketamine is a noncompetitive NMDA receptor antagonist and 
the anesthetic effects of ketamine are thought to result primarily from NMDA receptor 
blockade.  For example, the ketamine induced increase in dopamine release (discussed 
above in the section on monoamines (Aalto et al., 2005, Lindefors et al., 1997, Lorrain et 
al., 2003, Moghaddam et al., 1997)) is mediated by NMDA receptors.  Studies measuring 
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glutamate show that chronic treatment with ketamine decreases cerebrospinal fluid 
glutamate levels in rats (Tomiya et al., 2006).  During cerebral ischemia glutamate 
transporters reverse and release glutamate into the extracellular space causing neuronal 
damage (Sakai and Amaha, 2000).  Intravenous anesthetics are thought to be 
neuroprotective by decreasing this glutamate release into the extracellular space (Sakai 
and Amaha, 2000).  In Chinese hamster ovary cells transfected with a cloned human glial 
glutamate transporter, ketamine decreased glutamate-induced outward currents 
suggesting that ketamine modulates glutamate transporters in vitro (Sakai and Amaha, 
2000).  Many studies have investigated the role of glutamatergic signaling and the 
dissociative state that is produced by ketamine anesthesia.  Ketamine increases glutamate 
release in the nucleus accumbens (Razoux et al., 2007) and prefrontal cortex of rat 
(Lorrain et al., 2003).   Ketamine also increases anterior cingulate glutamate activity in 
humans (Rowland et al., 2005).  These region-specific increases in glutamate likely 
account for some of the dissociative properties produced by ketamine anesthesia. 
2.4  ACh: Ketamine modulates cholinergic neurotransmission in multiple brain 
regions and at both muscarinic and nicotinic cholinergic receptors.  Many studies have 
demonstrated that ketamine is a noncompetitive inhibitor at nicotinic ACh receptors 
(Coates and Flood, 2001, Furuya et al., 1999).  The inhibition of neuronal nicotinic ACh 
receptors by ketamine is subunit dependent, and  nicotinic receptors that contain the β1 
versus β2 subunit are more sensitive to ketamine (Yamakura et al., 2000).  Additionally, 
the presence of a single amino acid in the extracellular transmembrane region of the α7 
subunit of nicotinic receptors determines whether ketamine can inhibit nicotinic receptor 
currents (Ho and Flood, 2004).  These data are consistent with the interpretation that 
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ketamine produces anesthesia, in part, by modulating nicotinic ACh receptors.  The story 
is complicated, however, because the S enantiomer of ketamine is three times more 
potent than the R enantiomer, yet in vitro the two enantiomers inhibit neuronal nicotinic 
ACh receptor currents equally (Sasaki et al., 2000).  In contrast to the prior study, these 
data suggest that the anesthetic effects of ketamine are unlikely to be mediated primarily 
through nicotinic receptor signaling (Sasaki et al., 2000).  Another mechanism by which 
ketamine might modulate cholinergic neurotransmission is through muscarinic ACh 
receptors.  Fewer studies have investigated the effects of ketamine on the five subtypes of 
muscarinic cholinergic receptors.  Ketamine has been shown to inhibit M1 muscarinic 
ACh receptor currents in vitro (Durieux, 1995).  Consistent with the idea that ketamine 
anesthesia modulates ACh neurotransmission, repeated administration of ketamine causes 
up regulation of muscarinic ACh receptors in the forebrain (Morita et al., 1995). 
 Several studies have determined the effect of ketamine on brain ACh release in 
vivo.  Two studies demonstrated that systemically administered ketamine increased 
frontal (Kikuchi et al., 1997) and prefrontal (Nelson et al., 2002a) ACh release in rat.  
These data are difficult to interpret relative to the present chapter because cortical ACh 
promotes waking consciousness.  As noted above, ketamine is a dissociative anesthetic 
and the increase in cortical ACh release may contribute to the ability of ketamine to 
activate the bispectral index (Mashour, 2006a).  Intravenous delivery of ketamine as well 
as local ketamine administration to cat pontine reticular formation decreases ACh release 
and inhibits REM sleep (Lydic and Baghdoyan, 2002).  The finding that ketamine 
increases ACh release in cortex (Kikuchi et al., 1997), (Nelson et al., 2002a) and 
decreases ACh release in the reticular formation (Lydic and Baghdoyan, 2002) again 
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emphasizes that efforts to elucidate the neurochemical regulation of sleep and anesthesia 
can anticipate results to vary as a function of brain region.  Thus, we consider the 
postulate of a single “anesthesia center” in the brain to be an unhelpful throwback to the 
hope for a single, unifying mechanism. 
2.5  Adenosine:  Only one study was identified that investigated the role of 
adenosine in the mechanism of action of ketamine.  That study found that an adenosine 
A2A receptor agonist blocked ketamine induced hyperactivity, suggesting that adenosine 
or adenosine receptors may somehow contribute to ketamine induced locomotor 
activation (Mandryk et al., 2005).  Adenosine is an important modulator of physiological 
sleep and alertness during wakefulness, and future studies examining the effects of 
ketamine on the actions of adenosine in the basal forebrain and prefrontal cortex are 
likely to contribute to a mechanistic understanding of ketamine induced alterations in 
arousal state. 
 
II.  VOLATILE ANESTHETICS ALTER NEUROTRANSMITTERS THAT 
REGULATE SLEEP AND WAKEFULNESS.   This section selectively highlights the 
effects of isoflurane and sevoflurane, the most studied and widely used inhaled 
anesthetics (Table 2), on endogenous sleep-related molecules that include monoamines, 
ACh, GABA, glutamate, and adenosine. 
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Table A.2. Volatile Anesthetic Agents and Sleep-Related Neurotransmitters. 
The number of peer reviewed publications derived from a PubMed search ranging from 
1997 to 2007 in which the title listed both the volatile anesthetic (first column) and the 
endogenous neurotransmitter molecule (columns 2 through 6) is presented in this table.  
The right-most column summarizes the total number of citations for each agent.  The 
bottom right cell gives the total number of studies found that investigated the effects of 




Anesthetics Monoamines GABA Glutamate Acetylcholine Adenosine Total 
Isoflurane 14 13 12 8 7 54 
Sevoflurane 3 3 2 3 0 11 
Nitrous 3 2 3 2 0 10 
Xenon 3 1 1 2 1 8 
Desflurane 0 0 0 0 1 1 
Total 23 19 18 15 9 84 
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3.  Isoflurane 
Ether, nitrous oxide, and chloroform were among the first molecules recognized 
for their anesthetic properties during the 1840s.  Isoflurane, a halogenated ether, was 
developed in 1965 and entered clinical practice in the late 1970s (Eger, 1981).  Isoflurane 
binds to a specific site on the GABAA receptor to enhance neuronal inhibition.  
Additionally, isoflurane alters neurotransmission by varying the effects of many other 
sleep-regulating neuromodulators.  Whether the effects of isoflurane on the transmitter 
systems discussed below are direct or indirect remains to be determined. 
3.1  Monoamines:  Few studies have investigated the role of serotonergic 
neurotransmission in isoflurane anesthesia.  The medullary hypoglossal nucleus 
innervates the genioglossal muscles of the tongue and genioglossal muscles can obstruct 
patency of the airway.  Endogenous serotonin excites hypoglossal neurons (Berger et al., 
1992) and isoflurane depresses the excitatory effect of serotonin on hypoglossal 
motoneurons in dogs (Brandes et al., 2007).  Isoflurane also decreases hippocampal 
serotonin levels in wild type and serotonin transporter knockout mice (Whittington and 
Virag, 2006).  These results indicate that the mechanism by which isoflurane decreases 
hippocampal serotonin levels is independent of the serotonin transporter.  Decreases in 
serotonin levels persisted for several hours after cessation of isoflurane (Whittington and 
Virag, 2006).  Hippocampal serotonin contributes to cognition and affect, and these data 
encourage additional studies to determine if isoflurane-induced decreases in hippocampal 
serotonin cause subsequent behavioral consequences. 
Nitrous oxide and isoflurane are commonly coadministered and nitrous oxide 
produces analgesia, in part, by altering norepinephrine release in the spinal cord.  
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Electrophysiological data show that isoflurane and norepinephrine each enhanced 
inhibitory postsynaptic currents in rat substantia gelatinosa neurons (Georgiev et al., 
2006).  Coadministration of isoflurane and norepinephrine produced a greater increase in 
inhibitory postsynaptic currents than either drug alone, suggesting that isoflurane may 
produce analgesia, in part, by modulating norepinephrine neurotransmission at the level 
of the spinal cord dorsal horn (Georgiev et al., 2006). 
The preoptic area of the hypothalamus contains NREM sleep promoting neurons 
and is important for thermoregulation (reviewed in Ref. (Kumar et al., 2007)).  General 
anesthetics disrupt thermoregulatory control by neural mechanisms that remain unclear.  
Isoflurane increases preoptic area norepinephrine release in rat brain slices, suggesting 
that enhanced norepinephrine signaling in the hypothalamus may contribute to 
hypothermia during isoflurane anesthesia (Kushikata et al., 2005).  
Histaminergic neurons in the tuberomammillary nucleus of the posterior 
hypothalamus are an important component of wakefulness promoting neuronal systems 
(reviewed in Ref. (Passani et al., 2007)).  However, few studies have investigated the 
effects of volatile anesthetics on histaminergic neurotransmission.  One study 
investigated histamine metabolism in rat hypothalamus and found that isoflurane altered 
histamine turnover differentially in the anterior versus the posterior hypothalamus 
(Hashimoto et al., 1998).  Isoflurane was shown to increase histamine levels by inhibiting 
histamine degradation in both the anterior and posterior hypothalamus.  However, 
histamine degradation was increased during the post-isoflurane recovery period only in 
the posterior hypothalamus (Hashimoto et al., 1998).  The post-anesthesia increase in 
histamine turnover within the posterior hypothalamus is consistent with the wakefulness 
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promoting role of both histamine and the posterior hypothalamus.  In contrast, the 
anterior hypothalamus contains sleep promoting GABAergic neurons that do not respond 
to histamine (Gallopin et al., 2000).  These data showing brain region specific effects of 
isoflurane on histamine metabolism (Hashimoto et al., 1998) encourage future studies 
examining the effects of isoflurane on synaptic transmission within the anterior and 
posterior hypothalamus.  Such studies can be expected to yield mechanistic insights into 
how anesthetics alter states of consciousness. 
Dopamine is wakefulness promoting in animals and in humans (Lydic and 
Baghdoyan, 2005a).  For example, intracerebroventricular administration of dopamine 
D1 and D2 receptor agonists during physiological sleep in rats causes an increase in 
wakefulness, an increase in motor activity, and a decrease in sleep (Isaac and Berridge, 
2003).  Isoflurane increases basal dopamine release and dopamine metabolites in rat 
striatum in vivo (Adachi et al., 2005, Adachi et al., 2008, Keita et al., 1999) and in rat 
striatal slices ex vivo (Keita et al., 1999).  Dopamine transporter knock out mice show an 
increase in wakefulness and a decrease in NREM sleep (Wisor et al., 2001).  Positron 
emission tomography studies in rhesus monkey (Votaw et al., 2003) and in human 
(Votaw et al., 2004) demonstrated that dopamine transporter binding in the striatum 
decreases during isoflurane anesthesia.  These studies suggest that isoflurane increases 
dopamine levels by inhibiting dopamine reuptake.  In vitro experiments confirm that 
isoflurane causes internalization of the dopamine transporter (Byas-Smith et al., 2004).   
Emergence from anesthesia can be associated with an excitatory agitation phase, 
particularly in preschool children (Bortone et al., 2006).  Striatal dopamine may 
contribute to this emergence reaction.  In mice, recovery from isoflurane anesthesia is 
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characterized by increased locomotor activity and increased dopamine turnover in the 
nucleus accumbens and striatum (Irifune et al., 1997).  The importance of investigating 
these mechanisms in multiple brain regions is demonstrated by the fact that dopamine 
levels within the cortex and nucleus accumbens are greater during the activated states of 
wakefulness and REM sleep (Lena et al., 2005), whereas dopamine levels in the locus 
coeruleus and amygdala do not change across the sleep wake cycle (Shouse et al., 2000). 
3.2  GABA:  GABAA receptors are an important target for inhalation anesthetics 
and contain a binding site for isoflurane (Mashour et al., 2005).  Clinically relevant 
concentrations of isoflurane reduce the amplitude and extend the decay of GABA evoked 
currents by slowing the rate of GABA unbinding from recombinant GABAA receptors 
(Hapfelmeier et al., 2001a).  Isoflurane enhances GABAA receptor mediated currents in 
cultured rat cerebral cortical neurons (Ming et al., 2001) and, at clinically relevant 
concentrations, inhibits both the release and reuptake of GABA in mouse cortical brain 
slices (Liachenko et al., 1999).  Isoflurane also increases the binding of the 
benzodiazepine receptor antagonist 11C-flumazenil to GABAA receptors in human cortex 
and cerebellum, as demonstrated by positron emission tomography (Gyulai et al., 2001).  
Further evidence that isoflurane modulates GABAergic neurotransmission is 
demonstrated by the ability of an intrathecally administered GABAA receptor antagonist 
to increase the minimum alveolar concentration (MAC) value of isoflurane by 47% in 
rats (Zhang et al., 2001b). 
There have been few studies characterizing changes in endogenous GABA levels 
during states of sleep, wakefulness, or general anesthesia.  GABA levels during sleep are 
increased above waking levels in cat dorsal raphe nucleus (Nitz and Siegel, 1997a), locus 
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coeruleus (Nitz and Siegel, 1997b), and posterior hypothalamus (Nitz and Siegel, 1996).  
These findings support the interpretation that GABAergic inhibition of these wakefulness 
promoting monoaminergic nuclei contributes to the generation of physiological sleep.  
Compared to waking levels, isoflurane has been shown to decrease GABA levels in rat 
basal forebrain and somatosensory cortex (Dong et al., 2006).  Preliminary data from cat 
also show that GABA levels in the substantia innominata region of the basal forebrain are 
lower during isoflurane anesthesia than during wakefulness (Vanini et al., 2007).  
GABAergic input to the cortex from the basal forebrain can cause excitation by inhibiting 
cortical inhibitory interneurons (Freund and Gulyas, 1991, Freund and Meskenaite, 1992, 
Manns et al., 2000).  Thus, the isoflurane induced decrease in cortical GABA (Dong et 
al., 2006) is consistent with the fact that isoflurane decreases cortical activation and slows 
the cortical EEG.  Interestingly, isoflurane caused no change in posterior hypothalamic 
GABA levels (Dong et al., 2006).  Thus, even during states of general anesthesia there 
are brain site specific changes in GABAergic transmission. 
The capability of isoflurane to produce anesthesia is dependent on the 
composition of GABAA receptor subunits.  For example, a mutation in the α1 subunit of 
the GABAA receptor makes the receptor insensitive to isoflurane (Borghese et al., 2006).  
The ability of isoflurane to enhance GABA evoked GABAA receptor currents in cultured 
Sf9 cells is dependent on the presence of the γ2s subunit (Yamashita et al., 1999).  
GABA-mediated currents have been studied using an in vitro expression system 
transfected with recombinant GABAA receptors, and dual effects were reported 
(Neumahr et al., 2000).  At clinically relevant concentrations isoflurane was shown to 
potentiate GABA-mediated currents, and at higher concentrations isoflurane inhibited 
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GABA currents (Neumahr et al., 2000).  The potentiating effects that predominate at 
lower concentrations are thought to be relevant for the mechanism of isoflurane action.  
Studies in rat indicate that spinal GABAA receptors can contribute to immobility caused 
by isoflurane (Zhang et al., 2001a).  The role of GABAA receptors in mediating 
immobility is not straight forward.  For example, pharmacological blocking studies from 
this same group conclude that the immobilizing effect of isoflurane is not mediated by 
GABAA receptors (Sonner et al., 2003).  Transgenic mice have been used in an effort to 
clarify which components of the GABAA receptor mediate immobility caused by 
isoflurane.  Mice with a knock-in mutation in the β3 subunit of the GABAA receptor are 
less sensitive to the immobilizing action of isoflurane (Lambert et al., 2005).  
3.3  Glutamate:  One mechanism by which isoflurane has been proposed to cause 
anesthesia is by inhibiting excitatory neurotransmission.  Glutamate is the major 
excitatory amino acid transmitter in the brain, and the effects of glutamate can be reduced 
by decreasing its release, increasing its uptake, or blocking its receptors.  Glutamate 
transporters are located on neurons and glia, and take up extracellular glutamate to 
regulate synaptic glutamate levels.  Uptake is the major inactivation mechanism for 
glutamate, as it is not enzymatically degraded. 
Isoflurane has been shown to reduce glutamate release in isolated nerve terminals 
derived from rat cortex, hippocampus, and striatum (Larsen et al., 1998, Lingamaneni et 
al., 2001).  Isoflurane decreases glutamate release in rat hippocampal (Winegar and 
MacIver, 2006) and cerebral cortex slices (Liachenko et al., 1999).  At greater 
concentrations, however, isoflurane also inhibits glutamate uptake (Liachenko et al., 
1999).  The authors suggest that the effects of isoflurane depend upon a balance between 
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inhibition of release and inhibition of reuptake (Liachenko et al., 1999).  Several other 
studies have shown that isoflurane increases glutamate uptake.  In cultured rat glial cells, 
isoflurane increases glutamate uptake via glutamate transporters (Zuo, 2001) and in vivo 
inhibitors of glutamate transporters increase MAC for isoflurane in rat (Cechova and 
Zuo, 2006).  Isoflurane also increases glutamate uptake in rat cerebral cortex 
synaptosomes (Larsen et al., 1997).  Five types of glutamate transporters have been 
identified, and isoflurane increases the expression and activity of glutamate type 3 
transporters in cultured rat glioma cells (Huang and Zuo, 2003).  Isoflurane causes 
phosphorylation of a serine residue to activate the glutamate type 3 transporter and 
redistribute it to the plasma membrane (Huang et al., 2006). 
Glutamate causes excitation by activating NMDA receptors, and NMDA receptor 
activation requires the binding of both glutamate and glycine.  Isoflurane has recently 
been shown to inhibit NMDA receptors by binding to the glycine site (Dickinson, 2007).  
This finding suggests that blocking the excitatory effects of glutamate at NMDA 
receptors may be one mechanism underlying the anesthetic and neuroprotective effects of 
isoflurane. 
The above studies were performed using reduced preparations such as cell 
cultures, synaptosomes, or brain slices.  Few in vivo studies using intact animals have 
determined the effects of isoflurane on glutamatergic transmission.  In vivo microdialysis 
work using rat demonstrated that isoflurane differentially alters glutamate levels 
depending on brain region (Dong et al., 2006).  Compared to wakefulness, isoflurane 
causes a concentration dependent increase in glutamate levels in the basal forebrain, an 
increase in somatosensory cortex glutamate levels at one concentration only, and no 
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effect on glutamate levels in the posterior hypothalamus (Dong et al., 2006).  The 
mechanistic implications of the surprising finding that isoflurane increases basal 
forebrain glutamate levels are not yet clear. 
3.4  ACh:  Isoflurane modulates nicotinic and muscarinic cholinergic receptors, 
and the release of ACh.  Nicotinic receptors are comprised of five subunits, and several 
studies have investigated the role of various nicotinic ACh receptor subunits in the 
mechanism of action of volatile anesthetics (Violet et al., 1997).  Isoflurane at clinically 
relevant concentrations inhibits neuronal nicotinic ACh receptor currents expressed in 
vitro when the receptors contain the α4-β2 subunit combination (Yamashita et al., 2005).  
Isoflurane does not block the response of homomeric α7 nicotinic receptors to ACh when 
the anesthetic and the agonist are coadministered (Flood et al., 1997).  However, 
clinically relevant concentrations of isoflurane do inhibit homomeric α7 nicotinic 
receptors when the anesthetic is applied prior to ACh, or when ACh is applied in high 
concentrations (Flood and Coates, 2002).  These findings may be relevant in vivo, 
because α7 nicotinic receptors do occur in brain (Flood and Coates, 2002), and synaptic 
levels of neurotransmitters have been estimated to reach concentrations in the micromolar 
to millimolar range.  The effects of isoflurane on native (i.e., non-recombinant) nicotinic 
receptors also have been investigated (Matsuura et al., 2002).  Interestingly, both 
isoflurane and a structurally similar halogenated molecule that does not cause immobility 
but does have amnestic properties inhibits native neuronal nicotinic ACh receptors in rat 
medial habenula neurons (Matsuura et al., 2002).  Another structurally similar agent with 
neither immobilizing nor amnestic properties does not block nicotinic receptor-mediated 
currents (Matsuura et al., 2002).  These data suggest that the amnestic effects of 
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isoflurane may be mediated, in part, by nicotinic receptors in the medial habenula.  More 
in vivo studies are needed to determine if nicotinic ACh receptors are relevant for the 
production of anesthesia by isoflurane.  
There are five muscarinic cholinergic receptor subtypes, and isoflurane has been 
shown to inhibit M3 but not M1 muscarinic receptors (Nietgen et al., 1998).  M1 and M3 
receptors are structurally quite similar, thus different effects of the same anesthetic on 
these two subtypes implies that the site of action is quite specific.  More recently, the 
same investigators showed that isoflurane-induced inhibition of M3 receptor signaling is 
mediated by an increase in protein kinase C activity, but the site of action on the M3 
receptor has not yet been localized (Do et al., 2001).  Another study found that 
intracerebroventricular administration of the acetylcholinesterase inhibitor neostigmine or 
the muscarinic agonist oxotremorine to isoflurane anesthetized rats increases spontaneous 
limb and orofacial exploratory movements, indicating increased arousal (Hudetz et al., 
2003).  Cholinergic activation during isoflurane anesthesia also activates the cortex, as 
indicated by an increase in cross-approximate entropy of the bihemispheric frontal EEG 
(Hudetz et al., 2003).  These data are consistent with the interpretation that activation of 
central cholinergic neurotransmission can reverse some aspects of isoflurane anesthesia. 
Studies of intact brain using in vivo microdialysis report that isoflurane causes a 
dose dependent decrease in ACh release in rat cerebral cortex (Dong et al., 2006, 
Shichino et al., 1997), rat striatum (Shichino et al., 1997), and cat pontine reticular 
formation (Keifer et al., 1996).   The effect of isoflurane on ACh release varies with age.  
Isoflurane causes a significantly larger decrease in prefrontal cortex ACh release in old 
versus young rats (Jansson et al., 2004).  Future studies are needed to determine whether 
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aged rats show performance or memory deficits following isoflurane anesthesia.  Such a 
finding would support the interpretation that isoflurane-induced decreases in prefrontal 
cortex ACh release may contribute to increased post-operative delirium in the elderly. 
3.5  Adenosine:  Peroperative adenosine infusion in humans undergoing breast 
surgery decreases isoflurane requirement and decreases postoperative analgesic 
requirement (Segerdahl et al., 1995).  A similar study of patients undergoing shoulder 
surgery showed that adenosine reduces the requirement for isoflurane but has no effect on 
postoperative analgesic requirement (Segerdahl et al., 1996).  Although adenosine is well 
recognized to have antinociceptive effects (Boison, 2008), few studies have examined the 
possible role of adenosine in mediating the anesthetic effects of isoflurane.  In rat, 
isoflurane-induced reductions in focal cerebral ischemia are blocked by an adenosine A1 
receptor antagonist, indicating that this neuroprotective effect of isoflurane may be 
mediated by adenosine A1 receptors (Liu et al., 2006).  Isoflurane-induced activation of 
adenosine A1 receptors in primary cultures of rat hippocampal neurons also suppresses 
spontaneous calcium oscillations (Tas et al., 2003).  This study suggests that another 
mechanism by which isoflurane may be neuroprotective is by increasing adenosine levels 
(Tas et al., 2003).  
 
4.  Sevoflurane 
Sevoflurane is a nonflammable halogenated ether.  Sevoflurane is the newest 
inhalation anesthetic to be used in humans, and was introduced into clinical practice in 
the late 1980s .  The effects of sevoflurane on sleep-related neurotransmitters and 
neuromodulators are discussed below. 
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4.1  Monoamines:  Few studies have investigated the role of monoaminergic 
neurotransmission in sevoflurane anesthesia.  Sevoflurane produces a higher incidence of 
agitation during emergence from anesthesia in children than other general anesthetics 
(Bortone et al., 2006, Vlajkovic and Sindjelic, 2007).  Alpha2 adrenergic agonists, such 
as dexmedetomidine, decrease the frequency of emergence agitation by sevoflurane 
(Vlajkovic and Sindjelic, 2007), and α2 agonists inhibit the firing of noradrenergic locus 
coeruleus neurons (Aghajanian and VanderMaelen, 1982).  Noradrenergic neurons in the 
locus coeruleus promote wakefulness (reviewed in Ref. (Steriade and McCarley, 2005)), 
and sevoflurane directly excites noradrenergic locus coeruleus neurons in rat (Yasui et 
al., 2007).  Sevoflurane increases norepinephrine release in rat preoptic area (Anzawa et 
al., 2001).  Taken together, these data support the interpretation that noradrenergic 
neurotransmission contributes to emergence agitation produced by sevoflurane.  The 
monoamines dopamine and histamine also promote wakefulness (reviewed in Ref. 
(Steriade and McCarley, 2005)), and sevoflurane increases cortical dopamine release in 
rat brain slices by modulating dopamine transporters (Silva et al., 2007).  Sevoflurane 
also increases hypothalamic histamine levels in rat by inhibiting histamine metabolism 
(Hashimoto et al., 1998). 
4.2  GABA:  Sevoflurane, similar to many anesthetic molecules, enhances 
transmission at GABAA receptors.  Using recombinant α1, β2, γ2 GABAA receptors, 
isoflurane has been shown to increase the affinity of GABA and cause an open-channel 
block at the GABAA receptor (Hapfelmeier et al., 2001b).  These data suggest 
sevoflurane increases GABAergic transmission by binding to at least two different sites 
on GABAA receptors (Hapfelmeier et al., 2001b).  Sevoflurane also promotes GABA 
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evoked GABAA receptor chloride currents in isolated rat hippocampal neurons and 
modulates the GABA response by altering activation and decay phases of the current 
(Kira et al., 1998).  The modulation of hippocampal GABA receptors by sevoflurane is 
dependent on norepinephrine signaling, as coadministration of sevoflurane and 
norepinephrine have a large additive effect on inhibitory post synaptic currents and 
prolong the decay of the current (Nishikawa et al., 2005).  These results suggest that 
sevoflurane anesthesia is mediated, in part, by enhanced GABAergic neurotransmission.  
This interpretation awaits confirmation from in vivo studies. 
4.3  Glutamate:  General anesthetics are thought to produce their effects by the 
dual actions of increasing inhibitory GABAergic neurotransmission and inhibiting 
excitatory glutamatergic neurotransmission.  Sevoflurane has been shown to decrease 
calcium dependent glutamate release using synaptosomes isolated from human cerebral 
cortex (Moe et al., 2002).  Another study using rat cortical neurons also demonstrated 
that sevoflurane decreases glutamate release (Vinje et al., 2002).  These data encourage 
additional experiments designed to determine whether the sevoflurane-induced decrease 
in glutamate release contributes to the anesthetic effects of sevoflurane in vivo. 
4.4  ACh: Cholinergic neurotransmission is important for the regulation of sleep 
and waking consciousness, as well as anesthesia (Lydic and Baghdoyan, 1998, Lydic and 
Baghdoyan, 2005a).  Nicotinic receptors are inhibited by several anesthetics (Flood et al., 
1997, Violet et al., 1997), including sevoflurane (Scheller et al., 1997).  In humans, 
thalamocortical connectivity is suppressed when anesthetics induce loss of consciousness 
(White and Alkire, 2003).  Nicotinic receptors are densely expressed throughout the 
human thalamus (Gallezot et al., 2005), and microinjection of nicotine into rat central 
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medial thalamus reverses the sevoflurane induced loss of righting response (Alkire et al., 
2007).  These data suggest that suppression of midline thalamic cholinergic neurons 
contribute to sevoflurane induced unconsciousness.  
4.5  Adenosine: The PubMed review revealed no studies examining the role of 
adenosinergic neurotransmission in sevoflurane anesthesia. 
 
III.  CONCLUSIONS 
A recurring theme that emerges from any consideration of anesthetic alterations in 
brain neurochemistry is that the direction and magnitude of chemical change varies as a 
function of brain region and anesthetic agent.  There is no evidence that any single 
mechanism or brain region regulates the loss of waking consciousness during sleep or 
anesthesia.  Even within seemingly homogenous states of consciousness, the brain 
reveals widely disparate levels of activation (reviewed in Ref. (Mashour, 2006b, 
Nofzinger, 2006, Tononi, 2005)).  Such data make clear that understanding anesthetic 
alterations in consciousness will be limited unless the cellular and molecular mechanisms 
are elucidated on a brain region-by-region basis.  Progress can be made if future studies 
include local delivery of anesthetic molecules along with measurement of endogenous 
neurotransmitters in specific brain regions.  Another limitation concerns the lack of rigor 
regarding how anesthetic states of consciousness are classified.  The terms loss of 
righting reflex, sleep, sedation, hypnosis, and sleep-time are often used casually to reach 
desired conclusions regarding anesthesia-induced alterations in consciousness.  This lack 
of terminological rigor is particularly problematic for speculative extrapolations seeking 
to establish a link between pre-clinical studies and clinical implications.  A formal and 
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consistent classification of states based on physiological and behavioral traits (Hobson, 
1978, Plum and Posner, 1980) is essential and clinically relevant (McGuire et al., 2000).  
Drugs which selectively suspend consciousness are a logical path to understanding the 
neurological substrate of consciousness (Paton, 1984) and anesthesiology has unique 
potential to contribute to the clinical neuroscience of consciousness studies (Mashour, 
2004, Mashour et al., 2005, Mashour, 2006b).  Finally, judgments concerning the status 
of consciousness studies for anesthesiology should be tempered by expectations that 
incorporate an evolutionary perspective.  Neurochemical networks that evolved to 
generate the loss of waking consciousness during sleep are the most logical substrates 
through which anesthetic molecules eliminate waking consciousness.  Continuing efforts 
by anesthesiologists to understand consciousness will be promoted by research paradigms 
that incorporate the specific brain regions and neurochemical modulators of sleep. 
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